

May 7, 2024

## ***CURRICULUM VITAE***

### **KENNETH GABRIEL CASTRO, MD, FIDSA**

#### **Personal Data**

Born: January 17, 1953  
San Juan, Puerto Rico

Citizenship: U.S.A.

Married: Irene Martinez-Castro

Title(s): Professor (Clinical & Research Track)  
Hubert Department of Global Health  
& Department of Epidemiology  
Rollins School of Public Health  
and  
Adjunct Professor  
Division of Infectious Diseases  
Department of Medicine  
School of Medicine  
Emory University

Co-Director, Emory Tuberculosis Center

Director, Emory Hubert H. Humphrey Fellowship Program

Senior TB Scientific Advisor  
Office of Infectious Disease, Bureau for Global Health  
U.S. Agency for International Development

Senior Advisor & Guest Researcher (non-compensated)  
National Center for State, Tribal, Local, and Territorial Public  
Health Infrastructure and Workforce (NCSTLTPHIW)  
Centers for Disease Control and Prevention

Fellow, Infectious Diseases Society of America (FIDSA)

Assistant Surgeon General (RADM/O7 rank)  
U.S. Public Health Service (Retired)

Work address: 1518 Clifton Road NE, RRR Room 634  
Atlanta, Georgia 30322

Work e-mail: kcastro@emory.edu Personal e-mail: kgcastro1@gmail.com

## **Education**

Colegio San Ignacio High School	Graduate, 1970
University of Puerto Rico	B.S., 1974
Northeastern University	M.S. Candidate, 1976
State University of New York at Stony Brook School of Medicine	M.D., 1980

## **Postgraduate Training**

Internship	Internal Medicine, Residency Program in Social Medicine (RPSM), Montefiore Medical Center Albert Einstein College of Medicine, New York	1980-81
Residency	Internal Medicine, RPSM, Montefiore Medical Center Albert Einstein College of Medicine, New York	1981-83
Epidemiology	Epidemic Intelligence Service Centers for Disease Control and Prevention Atlanta, Georgia	1983-85
Fellowship	Division of Infectious Diseases Department of Medicine Emory University School of Medicine Atlanta, Georgia	1988-89
Scholars Program	Public Health Leadership Institute Cohort VII Centers for Disease Control and Prevention University of California	1997-98
National Preparedness Leadership Institute Program	Harvard School of Public Health Harvard Kennedy School of Government Cohort V Cambridge, Massachusetts	2008-09

## **Other Training**

Introduction to Computer Usage Centers for Disease Control	August 1983
Epidemiologic Report Writing & Consultation Centers for Disease Control	December 1983
Laboratory Assays for HIV Antibodies and Antigens, Centers for Disease Control	February 1988
Application of Polymerase Chain Reaction Technology, Centers for Disease Control	September 1989
HHS Executive Leadership Training and Annual Recertification in Security Awareness, Foreign Travel Safety, Records Management	Annual, 2005-2014
USAID Annual Training and Recertification in Security Awareness, Foreign Travel Safety, Records Management	2014- Present

## **Honors and Awards**

Second Honors & Cooperation Rating Award Colegio San Ignacio	1970
Member of the Biology Honorary Society, Tri Beta	1973
Scholarship Award, Mended Hearts Association	1980
Offered Andrew B. Mellon Fellowship in Clinical Epidemiology, Johns Hopkins University	1983
Unit Commendation Award, U.S. Public Health Service	1983
Commendation Medal, U.S. Public Health Service	1987
Outstanding Unit Commendation Award, U.S. Public Health Service	1989
Nominated for Charles C. Shepard Science Award, Centers for Disease Control	1989
Unit Commendation Award, U.S. Public Health Service	1990
Commendation Medal, U.S. Public Health Service	1991

Unit Commendation Award, U.S. Public Health Service	1991
Annual Service Award, Latino Caucus American Public Health Association	1991
Outstanding Service Medal, U.S. Public Health Service	1992
Alexander D. Langmuir Award (manuscript coauthor) Centers for Disease Control	1992
Co-recipient, Charles C. Shepard Science Award, Centers for Disease Control and Prevention (CDC)	1993
Coauthor of second publication nominated for Charles C. Shepard Science Award, CDC	1993
Honor Award Certificate National Center for Infectious Diseases, CDC	1993
Unit Commendation Awards (two), U.S. Public Health Service	1993
Program Operations Group Honor Award, CDC	1993
Outstanding Service Recognition, CDC	1993
James H. Nakano Citation, CDC	1994
Outstanding Unit Citation, CDC	1994
Coauthor of publication nominated for Charles C. Shepard Science Award, CDC	1995
Unit Commendation Award, U.S. Public Health Service	1995
Alexander D. Langmuir Award (manuscript coauthor)	1996
Unit Commendation Award, U.S. Public Health Service	1996
Outstanding Unit Citation, U.S. Public Health Service	1996
Outstanding Instructional Product or Intervention Award (shared) International Society for Performance Improvement	1996

Senior Biomedical Research Service Award, CDC	1998
Dr. Arturo L. Carrión Award, Puerto Rico Society of Microbiologists, American Society of Microbiology Branch	1999
Unit Commendation, U.S. Public Health Service	2001
Outstanding Unit Commendation, U.S. Public Health Service	2004
NCHSTP Division Director's Award (shared)	2004
Unit Commendation, U.S. Public Health Service	2004
Outstanding Unit Citation, U.S. Public Health Service	2004
Outstanding Unit Citation, U.S. Public Health Service	2006
Juan Carlos Finlay Award, U.S. Public Health Service	2008
Global Response Service Award, U.S. Public Health Service	2009
Coauthor of publication nominated for Charles C. Shepard Science Award, CDC	2009
Foreign Duty Award, U.S. Public Health Service	2010
"Public Health Hero" Profile, <i>Lancet</i> 2011;377:1456	2011
Outstanding Unit Citation, U.S. Public Health Service	2011
Coauthor of publication nominated for Charles C. Shepard Science Award, CDC	2012
Distinguished Service Medal, U.S. Public Health Service	2013
Lifetime Achievement Award International Union Against Tuberculosis and Lung Diseases North America Region	2014
Honorary Public Health Advisor Award The Watsonian Society	2014
Lifetime Achievement Award U.S. Agency for International Development	2014
Lifetime Scientific Achievement Nomination Certificate Charles C. Shepard Science Award, CDC	2014

Dixie Snider Award (Recognizing a CDC employee who provided outstanding support, through partnerships, to advance national TB control and prevention) National Tuberculosis Controllers Association	2014
Special Award Recognizing Leadership and Contributions in Global TB Critical Path to Tuberculosis Drug Regimens (CPTR)	2014
Lifetime Scientific Achievement Nomination Certificate Charles C. Shepard Science Award, CDC	2015
Nominated for the Princess Chichibu Memorial TB Award 46 <sup>th</sup> Union World Conference on Lung Health	2015
Lifetime Scientific Achievement Award Charles C. Shepard Science Awards, CDC	2016

### **Professional Organizations**

- Member, American Epidemiological Society (AES) (August 2016-present)
- Fellow, Infectious Diseases Society of America (IDSA) (July 2015-present)  
Member (since 1988); Member, HIV Medicine Association (2002-present); and  
Member, IDSA Global Health Committee (2018–present)
- Member, American Thoracic Society (1994-2012)
- Member, International Union Against Tuberculosis & Lung Diseases (1994-  
present); Chair, TB/HIV Workgroup, TB Section, 1997-2000)
- Member, International AIDS Society (2002-present)
- Member, USPHS Commissioned Officers Association (1983-2014)
- Member, Association of Military Surgeons of the U.S. (Lifetime Member, 2003)
- Member, EIS Alumni Association (Lifetime Member)
- Member, American Medical Association (1976-2006)
- Member, American College of Physicians (1980-2010)
- Member, American Public Health Association (1983-2006; Governing Council,  
Epidemiology Section (2000-2002)
- Member, American Association for the Advancement of Science (1983-1998)

### **Licensure/Certifications**

- New York Medical License #151908 (inactive)
- Georgia Medical License #032358
- DEA Controlled Substance Registration Certificate #BC2505951
- Board Eligible in Internal Medicine (1983) and Infectious Diseases (1989)

## **Academic Appointments**

Professor (Clinical Track)  
Hubert Department of Global Health  
& Department of Epidemiology  
Rollins School of Public Health  
Emory University June 1, 2014–Present

Adjunct Professor of Medicine (without compensation)  
Division of Infectious Diseases, Department of Medicine  
Emory University School of Medicine Renewed 2020–Present

Co-Director, Emory Tuberculosis Center  
<https://tb.emory.edu/faculty/index.html> March 2020–Present

Director, Hubert H. Humphrey Fellowship Program  
Rollins School of Public Health, Emory University July 2021–Present

Associate Director, Administrative Core  
Emory/Georgia TB Research Advancement Center  
NIAID/NIH Award (Grant P30AI168386-01) April 2022–Present

## **Hospital Clinical Privileges**

Clinical Faculty Staff Physician  
Grady Health System Renewed 2023-2025

## **Professional Experience**

Titles: Professor (Clinical Track)  
Hubert Department of Global Health  
& Department of Epidemiology  
Rollins School of Public Health  
Emory University June 2014–Present

Senior TB Scientific Advisor, TB Division  
Office of Infectious Diseases  
Bureau for Global Health  
U.S. Agency for International Development Nov 2014–Present

Major duties/accomplishments: During 2014-2019 I reported directly to Dr. Carlos Del Rio (former Chair), and since 2020 to Dr. Usha Ramakrishnan, Chair, Hubert Department of Global Health, where I have my primary faculty appointment. I also hold a joint appointed as Professor, Department of Epidemiology. In both Departments I serve as Faculty Advisor to graduate fellows (e.g., Hubert H. Humphrey Fellowship Program), and other students enrolled in the Master of Public Health

(MPH), Executive MPH, and Doctoral (PhD) programs. In addition, I have lectured in the following graduate courses of the Rollins School of Public Health (specific course department number included in parenthesis): “Global Tuberculosis Update” (GH 500); “Tuberculosis, a Re-emerging Health Problem” (EPI 542/ GH 562); “Global Issues in Antimicrobial Resistance” (EPI 558/ GH558); “Emerging Infectious Diseases” (EPI 562/ GH 518); “Humphrey Fellowship Seminar” (GH 585H); and “Introduction to Public Health” for doctoral students (PUBH 700). I also facilitate discussions with students on real-life case-scenarios covered during the core curriculum course in Global Health Ethics (GH 501). I serve as subject-matter expert consultant on academic curriculum development of TB and HIV courses and academic research in these fields, and continue to serve as thesis advisor, mentor, and/or chair to students’ MPH and PhD dissertation committees. Other academic activities include serving in the Training Advisory Committee of Dr. Henry Blumberg’s grant from NIH-Fogarty International Center for Global Infectious Diseases Training Program in Ethiopia and the Republic of Georgia. In June 2014 I was selected as member, National Policy Advisory Group, Coalition for Applied Modeling for Prevention (CAMP) for the Centers for Disease Control and Prevention (CDC) Grant # 1 1 NU38PS004650, and continue in this capacity. During June 2014-September 2022, I served as the designated Stop TB Partnership *ex-officio* member of the Technical Evaluation Reference Group (TERG), an independent evaluation advisory group, accountable to the Board of The Global Fund to Fight AIDS, Tuberculosis & Malaria for ensuring independent evaluation of the Global Fund business model, investments, and impact.

I am also the recipient of an Intergovernmental Personnel Act (IPA) Agreement award between Emory University and U.S. Agency for International Development (USAID). I report to Cheri Vincent, Chief, TB Division, in my appointment as Senior TB Scientific Advisor, TB Division, Office of Infectious Diseases, Bureau for Global Health, USAID. My responsibilities include contributing leadership and subject-matter expertise to the design and implementation of planned objective assessments and ongoing monitoring of the methodology and technical progress of USAID-sponsored TB prevalence surveys, TB transmission studies, laboratory diagnostic network assessments (including the detection of drug-resistant forms of TB), and clinical trials – to evaluate performance of infection control precautions and programs designed to diagnose people with TB and improve health outcomes with the use of optimal treatment regimens. Other areas of professional engagement include co-chairing USAID’s TB Contact Investigations Advisory Committee, contributing expert reviews to technical documents by the Stop TB Partnership, the WHO Global TB Programme, and special projects aimed at accelerating TB prevention and control in several host countries. These special projects have included: the introducing New Tools Project (iNTP) collaboration with Stop TB Partnership, the Quality of TB Care Assessments (QTCA), the development and implementation of guidance for USAID Country Missions to address TB in the context of COVID-19 pandemic, and the Airborne Infection Defense Platform (AIDP) to improve and enhance TB, COVID-19, and future



airborne pandemic preparedness and responses. I have also provided technical support to USAID teams and missions addressing HIV-associated TB under the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) Program in Angola and Botswana. I also offer technical leadership and support to ongoing implementation, monitoring, and evaluation of USAID TB Roadmaps in India and other selected priority countries. In July 2020 I was deployed to complete a six-week rotation as Deputy Lead, Technical and Implementation Support, Sustained Crisis Response Team (SCRT) for COVID-19. In September 2020 I served another six-week rotation as Incident Commander, SCRT for COVID-19 in the Bureau for Global Health, USAID.

Title: Adjunct Professor  
Division of Infectious Diseases, Department of Medicine  
Emory University School of Medicine Jan 2000–Present

Major Duties/accomplishments: Since January 2000, I have continuously held adjunct academic appointments with progressive promotions as Assistant Professor, Associate Professor, and now Professor of Medicine at Emory University School of Medicine. This adjunct academic appointment started while a career Medical Professional Officer in the U.S. Public Health Service Commissioned Corps, assigned to the Centers for Disease Control and Prevention. In this role, I maintain licensure, competency, and proficiency in my professional specialty by providing clinical services to outpatients enrolled in the Grady Infectious Diseases Program. I also retain up-to-date hospital privileges at Grady Health System. Other duties have included the mentorship of, and invited lectures to, medical students, post-graduate interns, residents, and fellows in infectious diseases. Over the years I have lectured in various invited seminars sponsored by the Division of Infectious Diseases.

Title: Coordinator  
Emory Hubert H. Humphrey Fellowship Program  
Rollins School of Public Health  
Emory University School of Medicine July 2021–Present

Major Duties/accomplishments: I was designated by Dr. Usha Ramakrishnan, Chair, Hubert Department of Global Health, Rollins School of Public Health, as Coordinator, Emory Humphrey Fellowship Program. In this capacity I provide technical leadership and oversight to this unique Fellowship Program award, sponsored by the U.S. Department of State's Bureau of Educational and Cultural Affairs, under the J. William Fulbright Foreign Scholarship Board and in cooperation with U.S. Embassies abroad. Emory University is one of 13 U.S. academic institutions hosting the Humphrey Fellowship Program. Our focus is to enhance leadership development and technical skills among international mid-career professionals to address a myriad of local and global public health challenges, foster professional networks and collaborations for our collective health and well-being. Other specific duties include mentorship of

approximately 12 post-graduate nondegree-seeking public health professionals/year.

Title: Co-Director, Emory Tuberculosis (TB) Center  
Rollins School of Public Health & School of Medicine  
Emory University March 2020–Present

Major Duties/accomplishments: Together with Drs. Neel Gandhi and Jyothi Rengarajan, we launched the Emory TB Center in March 2020 (<https://tb.emory.edu/index.html>) to enhance TB-related basic biomedical, epidemiological, clinical, translational, and public health research, service and practice. The Emory TB Center fosters and maintains several established partnerships among professionals and affected communities in local departments of health, the metro-Atlanta community, other institutions in the state of Georgia, and other national and international partners in Brazil, Ethiopia, Republic of Georgia, India, Kenya, and South Africa. The Center enables a collaborative environment for successful research funding applications, give students and postdoctoral trainees exposure to interdisciplinary and practicum opportunities, engage with professionals in clinical and public health practice, and raise public awareness of TB, and related comorbidities, as a major global health problem in need of attention. The Emory TB Center facilitated the successful competition of the Emory-Georgia TB Research Advancement Center (TRAC) awarded in 2022 by the U.S. National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH).

Title: Assistant Surgeon General  
Rear Admiral (O-7 rank/grade)  
U.S. Public Health Service  
Department of Health and Human Service May 2000–Oct 2014

Major duties/accomplishments: As a Flag Officer of the U.S. Public Health Service (PHS), I represented the top 1% leadership of the Commissioned Corps. In this capacity, I was called upon to provide the Surgeon General with advice in matters related to the Corps and PHS. I was continuously qualified to operate, and served, in promotion and retirement boards for Commissioned Corps Officers. I chaired the Scientist Chief Professional Officer Nomination Board, January 2005. I also provided a representational role for the USPHS and the Office of the Surgeon General.

Title: Commanding Flag Officer, CDC/ATSDR Commissioned Corps  
Centers for Disease Control and Prevention/  
Agency for Toxic Substances Disease Registry Sept 2008–Oct 2014

Major duties/accomplishments: As Commanding Flag Officer, CDC/ATSDR Commissioned Corps, I was the designated ranking Flag Officer charged with providing Agency oversight, mentorship, and guidance to nearly 900 Officers assigned to CDC/ATSDR. In this capacity, I reported directly to the Office of the Director, CDC/ATSDR, and coordinated with the Commissioned Corps

Personnel Office, CDC/ATSDR, the CDC and ATSDR representatives to the Surgeon General's Policy Advisory Council (SGPAC), other Flag Officers and Chief Professional Officers in the agency and served as liaison between HHS/CDC/ATSDR Director, Office of the Surgeon General (OSG), and Assistant Secretary for Health (ASH) on Commissioned Corps issues. I was responsible for ensuring that concerns of CDC/ATSDR Commissioned Corps Officers about significant policy issues were clear to the OSG, ASH, and Commissioned Corps leadership. I also ensured that leadership and policy decisions by ASH and OSG were promptly disseminated among Commissioned Corps Officers at CDC/ATSDR. As Commanding Flag Officer for the agency, I provided visibility and exemplified the core values of leadership, integrity, service, and excellence of the U.S. Public Health Service Commissioned Corps.

Title: Interim Director  
Division of HIV/AIDS Prevention  
National Center for HIV, Viral Hepatitis, STD, and TB Prevention  
Centers for Disease Control and Prevention Aug 2013–Aug 2014

Major duties/accomplishments: As Interim Director, Division of HIV/AIDS Prevention (DHAP), I oversaw an annual budget of approximately \$700 million and provided leadership and technical expertise to nearly 700 of CDC's multidisciplinary professionals in the implementation of the DHAP Strategic Plan and National HIV/AIDS Strategy (NHAS) released by the White House July 13, 2010 and signed by President Obama. These various professionals collaborated with U.S.-based state and local health departments, academic institutions, professional organizations, and international partners to develop and implement relevant clinical and operational research, evidence-based guidelines, and monitor progress towards meeting the 2010 National HIV/AIDS Strategy aimed at reducing new HIV infections, increase access to care and improve health outcomes for people living with HIV, and reduce HIV-related health disparities. During my tenure as Interim Director, DHAP published updated guidelines for Pre-Exposure Prophylaxis (PrEP) of HIV, and new HIV testing algorithm that relied on updated laboratory methods to enable the detection of persons with early HIV infection. In 2014 we published the second DHAP Progress Report accounting for advances made – and identified unmet needs – in NHAS and our strategic plan. Other draft guidance was developed for clearance and included recommendations for Persons Living with HIV/AIDS, reliance on mathematical modeling to inform and prioritize the implementation of high-impact interventions, and the successful re-competition of Capacity-Building Assistance (CBA) Cooperative Agreements between CDC and state/local and territorial health departments, Community-Based Organizations (CBOs), and other key partners (e.g., HIV

Medical Association of the Infectious Diseases Society of America and the HIV/AIDS Bureau, Health-Resources and Services Administration).

Title: Director, Division of Tuberculosis Elimination  
National Center for HIV, Viral Hepatitis, STD, and TB Prevention  
Centers for Disease Control and Prevention Jan 1993–Dec 2013

Major duties/accomplishments: I provided scientific and medical leadership for national tuberculosis prevention and control program activities in the United States, with a budget of approximately \$150 million and approximately 250 multidisciplinary professionals in Atlanta and other field assignments. Activities included strategic planning, scientific leadership and oversight, policy development, planning, coordinating, and implementing clinical and operational research. To accomplish program-relevant research activities, we sponsored two consortia that facilitated partnerships between the federal government (CDC), state and local health departments, and academic institutions: the TB Trials Consortium and TB Epidemiologic Studies Consortium. Based on the epidemiology of TB, and findings from research studies, I coordinated the development of national priorities for TB programs and formulation of evidence-based policies. A key function of CDC and the Division was to serve as the national TB program for the U.S. To accomplish this mission, I directed our Division's professional staff to work directly with state and local health departments in all states, territories, and selected large cities through 62 Cooperative Agreements, and in partnership with the National TB Controllers Association and Stop TB USA. Upon request, I also provided technical briefings and testimony to members of U.S. Congress and Senate. During my tenure, resources for TB programs were mobilized to enhance the identification, treatment, and cure of TB cases and the screening of high-risk populations for the provision of preventive therapy and launched an International Research and Programs Branch to address the global problem of tuberculosis. The global aspect of tuberculosis is directly reflected in the U.S. by a growing proportion of TB cases in people born outside the U.S. As a result of these combined activities, the incidence of TB cases steadily decreased over those 20 years -- following the unprecedented resurgence of tuberculosis in the United States from 1985 until 1992. Also, based on results of several epidemiologic investigations, I guided our professional staff to formulate evidence-based public health policy recommendations to prevent *Mycobacterium tuberculosis* transmission in health-care settings and airlines, to initiate clinical trials of new diagnostic methods and drugs for the prompt diagnosis and effective treatment of TB, and to revise and update recommendations for treatment of active TB, for targeted testing of high-risk populations, and for treatment of latent infection. Using two conservative scenarios and a mathematical model, we estimated that approximately 145,000-319,000 TB cases were averted during those two decades. The accompanying societal benefit of averted costs ranged from US\$ 3.1 billion to US\$ 6.7 billion excluding deaths, and from US\$ 6.7

billion to US\$ 14.5 billion, including deaths. Source: *Int J TB Lung Dis* 2016;20(7):926-933.

To address unmet needs in global TB, we initiated the Botswana-USA (BOTUSA) collaboration in 1995 to carry our program-relevant research in HIV-associated TB and used the findings to formulate updated evidence-based policies with the Botswana Ministry of Health and World Health Organization (WHO). We also planned and implemented interagency collaborations with USAID, WHO, and the International Union Against TB and Lung Diseases (IUATLD) to advance TB prevention and control, conduct surveillance and surveys to measure burden and extent of disease, and build public health and operational research capacity in several high priority countries. I also served as a founding member of the global Stop TB Partnership, its Coordinating and Executive Boards, and as technical advisor to the WHO Global TB Programme's Strategic and Technical Advisory Group.

Title: Co-Chair, Federal Tuberculosis Task Force  
Department of Health and Human Services Summer 1995–Dec 2013

Major duties/accomplishments: I facilitated communication and coordination among the various federal agencies which play pivotal roles in U.S. TB elimination efforts. The Federal Tuberculosis Task Force was established by HHS in December 1991 in response to the resurgent tuberculosis in the nation, and in 1992 developed and published the National Action Plan to Combat Multidrug Resistant Tuberculosis, which guided the mobilization of new resources for responding to the TB crisis in the United States. I was appointed by CDC to Co-Chair this Task Force in 1995. Over the ensuing years, Co-Chair, Dr. Christine Sizemore, National Institute for Allergy and Infectious Diseases (NIAID), NIH, and I worked to facilitate periodic teleconferences of this Task Force to discuss and monitor progress. Following the May 2000 publication of the Institute of Medicine (IOM) report "Ending Neglect: the Elimination of Tuberculosis in the United States," we guided this Task Force to develop an action plan in response to recommendations issued in the IOM report. This joint effort was accomplished by co-convening face-to-face Task Force meetings at NIH facilities in Bethesda, Maryland, in December 2000 and February 2001, followed by the draft report (formally approved in August 2003 by Secretary of Health Tommy Thompson) and the September 2003 desktop publication of "Federal Task Force Plan in Response to the Institute of Medicine Report, *Ending Neglect: the Elimination of Tuberculosis in the United States*." The initial description of extensively drug resistant tuberculosis (XDR TB) prompted us to convene a meeting of the Task Force in 2007 to identify challenges and derive consensus for an updated plan to address the urgent problem of XDR TB. This plan was published in the Morbidity and Mortality Weekly Report in 2009. Following those plans,

we convened an annual meeting of the Federal TB Task Force to monitor progress and identify new areas deserving of interagency collaboration.

Title: Acting Incident Management Commander  
2010 Haiti Earthquake Response  
CDC Emergency Operations Center January 2010

Major duties/accomplishments: As Acting Incident Management Commander, I provided scientific leadership and administrative oversight for the evolving response to the catastrophic 2010 Haiti Earthquake during the two-week period when Incident Manager CAPT Scott Dowell was deployed to Haiti. I was responsible for oversight for daily activities in CDC's Emergency Operations Center, reviewed daily update briefings to the Director, CDC/ATSDR, and participated in teleconference calls with the Associate Secretary for Preparedness and Emergency Response, HHS, to coordinate actions between CDC, other parts of HHS, and Department of Defense. During this early phase of the response, we initiated post-recovery medium- and long-term planning for public health reconstruction in Haiti.

Title: Acting Chief Health Officer  
2009 Pandemic Influenza A (H1N1) Response  
CDC Emergency Operations Center April–May 2009

Major duties/accomplishments: As Acting Chief Health Officer, I provided technical leadership and oversight for evidence-based guidelines to address the rapidly evolving pandemic during the early phases, while Chief Health Officer RADM Anne Schuchat was deployed to Washington, DC, to provide Congressional testimony and face-to-face briefings with HHS Secretary, Office of Surgeon General, and other federal agencies.

With Incident Management Commander RADM Stephen Redd, I was part of the leadership team to coordinate CDC's response to the 2009 influenza A (H1N1) pandemic. I helped review and prepare daily briefings for CDC Director, Associate Secretary for Preparedness and Emergency Response, and the Secretary, HHS. We also contributed to the formation of a team to provide formal decision briefs to inform the formulation of evidence-informed recommendations for diagnostic testing of persons with influenza-like illness – relying on new laboratory methods approved under FDA's Emergency Use Authorization, for pharmaceutical mitigation (i.e., antiviral treatment recommendations), and for non-pharmaceutical mitigation (i.e., recommendations for mass gatherings at a time of graduation commencements) to prevent the propagation of 2009 Influenza A (H1N1).

Title: Chief Health Officer  
2007 International Traveler with probable Extensively Drug Resistant TB  
CDC Emergency Operations Center May–July 2007

Major duties/accomplishments: As Chief Health Officer, I provided technical leadership and oversight to track a passenger with culture-

positive multidrug resistant (and probable extensively drug resistant) TB who traveled internationally in commercial aircraft. This incident resulted in the exposure of multiple other passengers to this very serious form of TB, and who needed to be contacted promptly to be evaluated for the possibility of recent TB infection. We implemented the principles contained in the International Health Regulations approved by the 2005 World Health Assembly/WHO, but not fully enacted. This work required frequent participation in secure/classified video-teleconferences with other key partners in Department of Homeland Security (DHS) and HHS. We successfully tracked the traveler and coordinated his medical evaluation and care in New York City, secured safe transport to his home state and subsequently to a specialty care setting. In addition, we directed an extensive international investigation of passenger contacts exposed to this patient during trans-Atlantic flights, to ensure their screening for TB. This response was coordinated in the midst of high media coverage and controversy. The high visibility of this response gave rise to Congressional briefings and testimony with colleagues from DHS. This incident also served to accelerate pending DHS policies for facilitated “do not board” actions to prevent the transmission of diseases of public health importance. In addition, results of this investigation were used by WHO to formulate and publish updated evidence-based guidelines in 2008 for the prevention of TB during commercial air travel.

Title: Special Assistant for HIV and TB,  
Office of the Deputy Director (HIV)  
Centers for Disease Control and Prevention May 1992–Dec 1992

Major duties/accomplishments: I was responsible for coordinating the planning and implementation of our agency's research in HIV and TB at a time when we were experiencing several outbreaks of multidrug-resistant TB cases affecting mostly persons who were also infected with HIV. This required a prompt response and mobilization of resources to assist health departments investigate and control these outbreaks. In coordination with other Federal health agencies, we developed the National Action Plan to Combat Multidrug Resistant Tuberculosis, published in 1992. This plan was used as the blueprint in our response to the unprecedented resurgence of TB and was recognized by the PHS Outstanding Unit Citation. I also coauthored a report describing the impact of both TB and HIV on duration and cost of hospitalization of patients in the United States.

Title: Consultant & Temporary Advisor  
Health Situation and Trends Assessment  
Pan American Health Organization July 1986–Dec 1992

Major duties/accomplishments: As a consultant to the Pan American Health Organization (PAHO), I served as a technical advisor on the development and implementation of programs to research and respond to the growing HIV public health problem in Latin America. I provided technical assistance to colleagues in Mexico, Guatemala, Colombia, Peru, Chile, Ecuador, Argentina, Brazil, and Venezuela. I also contributed to the development of

PAHO recommendations for the identification and management of HIV-associated opportunistic infections, first published in 1992; these have been used by clinicians throughout Latin America.

Title: Assistant Chief for Science,  
Epidemiology Branch, Division of HIV/AIDS,  
National Center for Infectious Diseases  
Centers for Disease Control and Prevention                      Sept 1990–May 1992

Major duties/accomplishments: As a senior medical epidemiologist, I was relied upon to help coordinate, implement, and investigate research activities aimed at understanding the routes of HIV transmission, and the occurrence of HIV-associated opportunistic infections (with emphasis on tuberculosis). I also coordinated and provided oversight to the revision of the classification system for HIV infection and the revision of the AIDS surveillance case definition. This revision was published in 1993 for use by clinicians and epidemiologists throughout the United States.

Title: Special Assistant to the Director for Science, AIDS Program,  
National Center for Infectious Diseases,  
Centers for Disease Control    July 1989–Sept 1990

Major duties/accomplishments: I coordinated policy development, and the implementation of epidemiologic research by the various scientists in the Division of HIV/AIDS and started the review of data on HIV classification systems to obtain the scientific basis for a revision of this system. This work required coordination with researchers and scientists throughout the United States and other countries.

Title: Fellow, Division of Infectious Diseases  
Emory University School of Medicine                                      July 1988–June 1989

Major duties/accomplishments: I was responsible for providing clinical consultation and advice on the diagnosis and treatment of infectious diseases in hospitalized patients. During that academic year, I rotated through various hospitals, including Grady Memorial Hospital, Emory University Hospital, Crawford Long Memorial Hospital, and the Atlanta Veterans Administration Hospital. I also completed the clinical requirements for subspecialty Boards in Infectious Diseases and analyzed the occurrence of tuberculosis at Grady Memorial Hospital to describe a significant increase from 1982 until 1989, associated with increases in HIV infection. Results from these analyses were presented in 1990 at the International AIDS Conference and at the Interscience Conference on Antimicrobial Agents and Chemotherapeutics (ICAAC).



Title: Medical Epidemiologist, AIDS Program  
Center for Infectious Diseases  
Centers for Disease Control

July 1983–June 1989

Major duties/accomplishments: After completing two years of training in applied epidemiology in CDC's EIS program, I designed and implemented various studies to elucidate the routes of HIV transmission. I also analyzed AIDS surveillance information to study and describe the disproportionate excess of AIDS in racial and ethnic minorities. The epidemiologic studies included interviews of AIDS patients with no risk factors, a case-control study of AIDS in Haitian-Americans residing in Miami and New York, multiple investigations of unusual AIDS cases, and a community-based HIV survey in Belle-Glade, Florida. The findings of these various research activities were presented at national and international scientific meetings and published in peer-reviewed scientific journals. Additionally, the findings of these various studies provided the evidence basis for targeted recommendations to prevent the transmission of HIV infection.

### **Uniformed Services Experience**

Active Duty Commissioned Officer, Commissioned Corps,  
U.S. Public Health Service

Rank: Assistant Surgeon General (Rear Admiral, O-7)

Retired with Honorable Discharge

July 2, 1983–November 1, 2014

### **Other Professional Positions/Contributions**

1. Associate Editor, International Journal of Tuberculosis and Lung Disease (June 1997- Present)
2. Clinical Associate Professor of Medicine, Emory University School of Medicine (July 2000- Present)
3. Volunteer Staff Physician, Infectious Diseases Program, Grady Memorial Hospital, Atlanta, Georgia (July 1989- Present)
4. Member, Scientific Advisory Committee, AIDS Research Consortium of Atlanta, Inc. (July 1989- July 1998)
5. Peer reviewer: Journal of the American Medical Association; American Journal of Public Health; Journal of Acquired Immune Deficiency Syndromes; Archives of Internal Medicine; Annals of Internal Medicine; Journal of Infectious Diseases; New England Journal of Medicine; International Journal of Tuberculosis and Lung Disease (Sept 1983- Present)
6. Consultant, Biomedical Research Unit, Global Programme on AIDS, World Health Organization (March 1990)

7. Member, Search Committee, Branch Chief, Division of Parasitic Diseases, NCID, CDC (1990)
8. Member, U.S. Secretary of Health and Human Services' Special Emphasis Oversight Committee on Science and Technology (May 1990- June 1992)
9. Member, Public Health Service Tuberculosis Task Force (May 1992- Present). Co-Chair (Summer 1995-December 2013)
10. Member, Search Committee, NIOSH Director, CDC (1993)
11. Member, Search Committee, Director, Division of Violence Prevention, NCIPC, CDC (1996)
12. Member, Tuberculosis Operational Research Steering Committee, Tuberculosis Programme, World Health Organization (May 1994- 1998)
13. Member, TB Committee, Infectious Diseases Society of America (IDSA) (1995-1998)
14. CDC/ATSDR Senior Biomedical Research Service Credentials Committee (December 1995- 1998)
15. Chair, TB/HIV Workgroup, Tuberculosis Committee, International Union Against Tuberculosis and Lung Diseases (October 1997- October 2002)
16. Member, Search Committee, Deputy Director, NCID, CDC (1998)
17. Member, Search Committee, 3 Division Directors, NCEH (Division of Birth Defects and pediatric Genetics; Division of Child Development, Disability, and Health; and Division of Emergency and Environmental Health Services) (1999)
18. Member, Search Committee, Director, Division of Quarantine, NCID, CDC (1999)
19. Member, Search Committee, Deputy Director for Science, CDC (1999)
20. Member, Search Committee, Director, Office of Smoking and Health, CDC (2000)
21. Member, Commissioned Officers Retirement Board, U.S. Public Health Service (2000- 2004)
22. Member, Governing Council, Epidemiology Section, American Public Health Association (2000- 2002)
23. Founding member, global Stop TB Initiative/Partnership (1998-2000).
24. Member, Search Committee, Director, Division of HIV/AIDS Prevention-Intervention Research and Support, NCHSTP, CDC (2001)

25. Technical Expert Reviewer, Tuberculosis Grants, Bill and Melinda Gates Foundation (October, 2001)
26. Member, Search Committee, Deputy Director, Office of Minority Health, CDC (2002)
27. Member, Search Committee, Division Directors (Birth Defects and Human Development/Disabilities), National Center on Birth Defects and Developmental Disabilities (2002).
28. Member, Peru National Tuberculosis Program Technical Review Team, Pan American Health Organization. (Visited Lima and Tacna, Peru. February 11-16, 2002).
29. Member, Executive and Coordinating Boards, World Health Organization-hosted global Stop TB Partnership (2001-December 2014)
30. Expert consultant, Working Meeting: Guidelines for the Therapy of HIV-Associated Opportunistic Infections. NIH Campus. Bethesda, Maryland. (April 15-16, 2002).
31. PAHO Expert Technical Consultant. Conference on the impact of health systems reform on the control and prevention of infectious diseases in Latin America. Havana, Cuba. (April 29-30, 2002).
32. Member, Search Committee, Division Director, Healthcare Quality Promotion, NCID, CDC (2003)
33. Member, Search Committee, Stop TB Partnership Executive Secretary (2003)
34. Member, Search Committee, Division Director, Division of Vector Borne Diseases, NCID, CDC (2003)
35. Chair, Nominating Committee, WHO Stop TB Partnership Coordinating Board Chair (2003)
36. Member, Search Committee, CDC Deputy Director for Science (2004)
37. Elected to Executive Board, WHO Stop TB Partnership (June 2004-present)
38. Associate Editor, Emerging Infectious Diseases Journal (December 2004-present)
39. Chair, Scientist Chief Professional Officer Nomination Board, Commissioned Corps, USPHS (January 27, 2005)
40. Chair, Selection Committee, Director, Global AIDS Program, NCHHSTP, CDC (January 2005)

41. Technical Consultant, Zambia Tuberculosis National Program Review (April 17-25, 2005)
42. Member, Working Group on TB, UN Millennium Project Task Force on HIV/AIDS, Malaria, TB, and Access to Essential Medicines (January 2002- May 2005)
43. Member, Selection Committee, Stop TB Partnership Kochon Prize (November 2005-present)
44. Chair, Special Emphasis Panel “Units for HIV/AIDS Clinical Trials Networks” (RFA05-002), National Institute for Allergy and Infectious Diseases, NIH (February 17, 2006)
45. Chair, Selection Committee, Director, Kenya-CDC Collaboration (April 2006)
46. Expert consultant, WHO Scientific and Technical Advisory Group (STAG) for tuberculosis (June 2006-present)
47. Co-Moderator, South Africa Medical Research Council Expert Consultation on Extensively Drug Resistant Tuberculosis (XDR TB). Johannesburg, South Africa. (Sept 7-8, 2006)
48. Acting Executive Secretary, Advisory Council for the Elimination of Tuberculosis (June 2006 – December 2008)
49. Co-Chair, CDC Title 42 Performance Review Board (November 2006)
50. Co-Chair, CDC Division Directors’ Council Steering Committee (December 2006- January 2009)
51. Member, CDC Compensations and Review Committee (2007- 2009)
52. Member, National and Global Public Health Committee, Infectious Diseases Society of America (2007- 2010)
53. Member, Vaccine Selection Advisory Committee, AERAS Global TB Foundation (January 2008- December 2010)
54. Global Alliance for TB Drug Development, Stakeholders Association member (2006-Present)
55. Global Stop TB Partnership TB REACH Program Steering Group (2010-Present)
56. Member, Technical Advisory Group, International Review of Republic of Korea’s 2020 TB Elimination Plan (Seoul, and Osong Health Technology Complex, Korean CDC, Korea. (Aug 21-27, 2011)
57. Critical Path Institute, Critical Path to TB Drug Regimens Advisory Panel (Nov 2011-Feb 2014)

58. Member, Joint Monitoring Mission, India's Revised National TB Control Programme and 5-year Plan 2013-2017 (Delhi and Mumbai, India. Aug 21-31, 2012)
59. Member, Selection Committee, Director, Division of HIV/AIDS Prevention, CDC. (Dec 2013-Aug 2014)
60. Member, National Policy Advisory Group, Coalition for Applied Modeling for Prevention (CAMP). [Centers for Disease Control and Prevention Grant # 1 1 NU38PS004650]. (June 2014- Present)
61. Associate Editor, *Public Health Reports* (July 2014- Present)
62. *Ex-Officio* Member, Technical Evaluation Reference Group (TERG), Global Fund to Fight AIDS, Tuberculosis, and Malaria (August 2014 - September 2022)
63. Member, and Gujarat State Site Visit Team Lead, Joint TB Monitoring Mission, India (Delhi and Gujarat State, India. April 8-25, 2015)
64. Promoted to Fellow category, Infectious Diseases Society of America (FIDSA). (July 24, 2015- Present)
65. Advisor Emeritus, Critical Path to TB Drug Regimens (CPTR) 2016 Workshop, Washington, DC. (April 4-7, 2016)
66. Member, and Team Leader for Amhara Region Field Visits. WHO and Ethiopia Federal Ministry of Health Joint Monitoring Mission, Mid-term review of Ethiopia's National Tuberculosis and Leprosy Program and National Strategic Plan, Addis Ababa and Bahir Dar, Ethiopia (January 16-31, 2017)
67. Member, USAID Technical assessment to investigate adverse treatment outcomes in patients with multidrug- and extensively drug-resistant tuberculosis, Democratic Republic of Congo (DRC). USAID and DRC National Tuberculosis Program, Kinshasa, DRC (March 18-27, 2017)
68. Member, WHO and Botswana Ministry of Health and Wellness Joint Monitoring Mission of HIV/AIDS, STIs, Hepatitis, and TB Programmes. Gaborone, Francistown, Kasane, and Serowe, Botswana (September 3-12, 2017)
69. Member, Global Fund for AIDS, Tuberculosis and Malaria Technical Evaluation Reference Group. Uganda Prospective Country Evaluation. Kampala, Uganda (September 16-23, 2017)
70. Member, WHO-USAID-CDC-Stop TB Partnership Mission to Assess Progress in Angola's National TB Program. Luanda, Angola (October 24-29, 2017)
71. Member, Ministry of Health and Family Welfare, Government of India-USAID Joint International Assessment of the Tuberculosis Diagnostic Network in India. Delhi, Lucknow, and Agra, India (October 30-November 10, 2017)

72. Member, Global Fund Against AIDS, TB and Malaria Prospective Country Evaluation Dissemination Workshop. Guatemala City, Guatemala (April 9-13, 2018)
73. Member, WHO Global Task Force on TB Impact Measurement, Glion-sur-Montreux, Switzerland (May 1-4, 2018)
74. Member, PAHO Monitoring Visit to Assess Mexico's National Tuberculosis Program. Ciudad Mexico, Mexico (October 15-19, 2018)
75. Chair, Vth Meeting of the Tuberculosis Technical Advisory Group, Pan American Health Organization. Washington, DC (December 4-5, 2017)
76. Member, Joint External Quality Assurance Mission of the Botswana TB Prevalence Survey. Gaborone, Botswana (May 12-23, 2019)
77. Member, WHO Strategic and Technical Advisory Group for TB. Geneva, Switzerland (June 11-13, 2019)
78. Lead Member, 2019 WHO-Government of India Joint Monitoring Mission to assess progress against the National Tuberculosis Strategic Plan 2017-2025: ending TB by 2025. Team Lead, Lucknow State site visits. Delhi, Lucknow, India (November 11-22, 2019)
79. Deputy for Technical and Implementation Support, Sustained Crisis Response Team (SCRT) for COVID-19 response, Bureau for Global Health, USAID (June 8 - July 5, 2020).
80. Deputy for Technical and Implementation Support, Sustained Crisis Response Team (SCRT) for COVID-19 response, Bureau for Global Health, USAID (September 9 - 27, 2020)
81. Incident Commander, Sustained Crisis Response Team (SCRT) for COVID-19 response, Bureau for Global Health, USAID (September 28 - October 18, 2020)
82. Co-Chair (with Dr. Gail H. Cassell), Committee of Innovations for Tackling Tuberculosis in the Time of COVID-19: A Two-Part Workshop, Forum on Microbial Threats, Board on Global Health, Health and Medicine Division, National Academies of Science, Engineering, and Medicine. (Virtual Workshops: July 22, September 14-16, 2021). <https://www.nationalacademies.org/our-work/innovations-for-tackling-tuberculosis-in-the-time-of-covid-19-a-two-part-workshop-series>
83. Appointed to the International Review Panel for National Tuberculosis Control in Singapore, Ministry of Health, Singapore, 06 June – 31 December 2022 (Site visit October 11-14, 2022)
84. *Ex-Officio* Member, USAID-sponsored SMART4TB Consortium Scientific Advisory Board (Mar 2023 – Ongoing)

85. Co-convenor (with Dr. Yukari Manabe), PW06 TB Workshop, ID Week 2023. Infectious Diseases Society of America. Boston, Massachusetts. October 11, 2023
86. Co-convenor (with Drs Yuka Manabe and Maunank Shah). TB Workshop, ID Week 2024. Infectious Diseases Society of America. Los Angeles, California. October 15, 2024.

**MPH Thesis Committee Chair/Co-Chair by Post-graduate student name, Degree (Concentration), Academic Year, and Thesis Title**

1. Ghuman, Parneet, MPH (GH) 2016: "Evaluating the costs associated with tuberculosis (TB) treatment, care, and services among low-income individuals in rural Guangxi, China" (<http://pid.emory.edu/ark:/25593/rjz35>)
2. Chitanvis, Maneesha Elizabeth, MPH (EPI) 2016: "Clinical risk assessment tools for the characterization of early warning indicators of HIV virologic failure in first-line antiretroviral therapy in an urban clinic in Kwazulu-Natal, South Africa" (<http://pid.emory.edu/ark:/25593/rkbfr>)
3. Gharbin, John, MPH (GH) 2017: "Prevalence and Treatment Outcome of Tuberculosis and Latent Tuberculosis Infection Among Newly Arrived Refugees in DeKalb County, January 2015-February 2016"
4. Probst, Jessica R, MPH (EPI) 2017: "Tumor Necrosis Factor-Antagonist Therapy Exposure Associated with Sputum Conversion by Eight Weeks among United States Tuberculosis Patients, 2010-2015"
5. Oppong-Twene, Philip, MPH (GH) 2017: "Impact of Active Case-Finding on Tuberculosis Transmission Among the Homeless in Fulton County, Georgia, 2010-2015: Secondary Data Analysis"
6. Jordan, Alexander, MPH (EPI) 2017: "Prevalence and Risk Factors of Tuberculosis Disease in South African Correctional Facilities in 2015"
7. Kim, Jennifer J, MPH (EPI) 2017: "Tuberculin Skin Test Result and Time to Sputum Culture Conversion Among Persons with Active Tuberculosis"
8. Morisseau, Nancy, MPH (GH) 2017: "Tuberculosis Screening Among Immigrants Entering the United States: An Analysis of Radiographic Findings of China, Mexico, Nepal, Philippines and Vietnam"
9. Soni, Tanushree, MPH (GH) 2017: "Cox Proportional Analysis to determine the predictors of Sputum Culture Conversion in Patients with Tuberculosis"
10. Tashpulatova, Lolakhon, MPH (GH) 2017: "Role of Comorbid Conditions Such as Diabetes, HIV, and Alcohol Abuse in Outcomes of TB Therapy: A Review of Literature"

11. Plunkett, Elizabeth, MPH (GH) 2017: "Operational Implications of Trachomatous Trichiasis Prevalence Estimation and Pilot Guide for Assessing Trachomatous Trichiasis in Low Burden Areas"
12. Stevenson, Kelsey, MPH (GH) 2017: "Epidemiology of HIV and tuberculosis in five South African correctional facilities"
13. O'Son, Lana C, MPH (GH) 2017: "Characterization of Tuberculosis (TB) in Lebanon: Epidemiology and Risk Factors for Extrapulmonary TB"
14. Reich, Jeremy S, MPH (EPI) 2017: "Impact of Repeated Prior Influenza Vaccination on Serum Hemagglutinin Inhibition Antibody Response to B/Victoria/Brisbane/60/2008-like virus in 2010-11 Inactivated Influenza Vaccine and Prior Seasonal Victoria and Yamagata Influenza B Lineage Components among Healthcare Personnel"
15. Lankford, Amanda, MPH (GH) 2017: "Survival Analysis Comparing HIV Infection Status and Time until Diagnosis in Tuberculosis Cases in the United States Foreign-Born Population by Region of Origin, 2005-2015"
16. Kinane, Catriona, MPH (GH) 2018: "A systematic review of the rates of completion of treatment and activation of disease in patients found to have latent tuberculosis infections after testing and before placement on Anti TNF-Alpha Blockers"
17. Patterson, Naomi, MPH (GH) 2018: "The Impact of Immune Activation on Infant BCG Vaccine Response"
18. Goughnour, Kenneth, MPH (GH) 2018: "Pediatric Risk Assessment Mapping Net(work): Mapping the Health Gaps for Children with Complex Medical Needs, Children with Disabilities, and Infectious Pediatric Illnesses"
19. Smith, Gillian, MPH (Epi) 2018: "Factors Associated with Ototoxicity among TB Patients Treated with Aminoglycosides"
20. Whitesell, Amy, MPH (Epi) 2018: "Multisite Evaluation of Phenotypic Mycobacterium tuberculosis Drug Susceptibility Testing Methods"
21. Chen, Lillian, MPH (GH) 2019: "Inapparent Infections Due to Emerging Infectious Diseases in Return International Travelers"
22. Dualeh, Mushtaq, MPH (GH) 2019: "Risk Factors Associated with Change in Body Mass Index (BMI) Among Persons Living with HIV (PLWH) and on Antiretroviral Therapy (ART) in the Copperbelt and Eastern Provinces of Zambia"
23. Jones, Cynthia N, MPH (Epi) 2019: "Leprosy in the Wake of Helminth Immunomodulation: A study on the impact of deworming on leprosy outcomes in Vale do Rio Doce, Brazil"



24. LaGattuta, Natalie R, MPH (GH) 2019: “Water, Sanitation, and Hygiene (WASH) Challenges and Non-WASH Challenges Western Ugandan Women Experience Utilizing Maternal Healthcare Facilities”
25. Milazzo, Katherine, MPH (GH) 2019: “Patient Satisfaction and Human Immunodeficiency Virus (HIV) Infection in Public Health Facilities in Gauteng, South Africa”
26. Siegel, Jolie, MPH (GH) 2019: “Influence of HIV Co-infection on Tuberculosis Treatment Outcomes in Children: A Systematic Review and Meta-analysis of the Literature”
27. Bruck, Marina, MPH (EPI) 2020: “Whose Job Is It Anyway? An Analysis of Views on Responsibility of Vector Control and Hotspots of Acceptance of Wolbachia Suppression Among Communities Organized to Prevent Arboviruses (COPA) Study Participants in Ponce, Puerto Rico”
28. Castor, Rebecca, MPH (GLEPI) 2020: “Post-Mass Drug Administration Serological Assessment of Lymphatic Filariasis and Onchocerciasis in Plateau State, Nigeria”
29. O’Connor, Stephanie, MPH (GH) 2020: “Presentation and Treatment Outcomes by Diabetes Status among Patients with Tuberculosis in Guam, 2015–2018”
30. Thyagarajan Rama V, EMPH (Prevention Sciences) 2020: “Retrospective Validation of Methicillin Resistant Staphylococcus Aureus Risk Assessment Tool against Nasal PCR screening in Hip and Knee Replacement surgeries”
31. Nath, Serei Vatana, MPH (GH) 2021: “Treatment Outcomes of Pulmonary Tuberculosis at Population Services International Clinic Networks, Myanmar: A Retrospective Cohort Study, 2012 – 2016”
32. Amanuel, Hanna, MPH (GH) 2022: “Identifying Key Gaps in Service for HIV-Exposed Infants within USAID Supported PEPFAR Programs”
33. Gonzalez-Montalvo, Myrna del Mar (GH) 2022: “Understanding the effect of COVID-19 on the management of non-communicable diseases in patients in a Federally Qualified Health Center in Puerto Rico”
34. Patel, Nisha (GH) 2022: “The Development of a Water, Sanitation, and Hygiene Training Manual for Community Health Workers in Low Resource Arid Regions: A Special Studies Project”
35. Taylor, Megan (GH) 2022: “Identifying Gaps in the Zoonotic Disease Burden of Central America”
36. Colton, Mia (GH) 2023: “The social determinants of health of dengue seroprevalence: A systematic review and meta-analysis”
37. Grube, Steven (EMPH) 2023: “Joint External Evaluations as Predictors of Excess Mortality During the COVID-19 Pandemic”

38. Kuo, Christina (GH) 2024: “Estimation of COVID-19 Vaccine Effectiveness against Mortality During April to December 2022 of COVID Infections in Taiwan”
39. Salthouse, Abigail (EPI) 2024: “Clinical markers of severe TB disease in the United States before and after the onset of the COVID-19 pandemic, 2010-2020”
40. Mbogo, Loice (GH) 2024: “Longitudinal monitoring of HIV virologic suppression among people who inject drugs and on Dolutegravir-containing antiretroviral therapy in Kenya”
41. Boulding, MaryGrace (GH) 2024: “TB sensitization measured by interferon gamma and non-interferon gamma cytokines among South African Infants”

**PhD Thesis Committee Member by Post-graduate student name, Degree (Concentration), Academic Year, and Thesis Title**

1. Haddad, Maryam, PhD, 2018 (EPI, Rollins School of Public Health, Emory University): “Assessing the potential impact of bias in accurate estimates of the prevalence of TB infection in the U.S. population over four decades”
2. Kyaw, Nang T, PhD Candidate, 2020 (EPI, Georgia State University): “Estimating the impact of chronic communicable and non-communicable diseases on clinical outcomes in people living with HIV in Myanmar”

**Mentoring (Post-graduate Students, Junior Faculty, Others), Emory University**

1. Neha Acharya (MPH candidate GH 2017)
2. Tyler Chavers (MPH candidate GH 2017)
3. Maneesha Chitanvis (MPH GH 2016)
4. Marcos Coutinho-Schechter, MD (ID Fellow 2015-17, Advisory Committee Member)
5. Parneet Ghuman (MPH GH 2016)
6. John Gharbin (MPH candidate GH 2017)
7. Charles Harless (MPH candidate GH 2017)
8. Alexander Jordan (MPH candidate GH 2017)
9. Amanda Lankford (MPH candidate GH 2017)
10. Hannah Lofgren (MPH GH 2016)
11. Nancy Morisseau (MPH candidate, GH 2017)
12. Kelsey Patel (MPH candidate Epi 2017)
13. Jeremy Reich (MPH candidate EPI 2017)

14. Philip Oppong-Twene (MPH candidate GH 2017)
15. Tanushree Soni (MPH candidate GH 2017)
16. Kelsey Stevenson (MPH candidate GH 2017)
17. Lolakhon Tashpulatova (MPH candidate GH 2017)
18. Conor Cahalan (MPH candidate GH 2018)
19. Nisha George (MPH candidate Epi 2018)
20. Kenneth Goughnour (MPH candidate Epi 2018 & Georgia Tech)
21. Anum Khan (MPH candidate GH 2018)
22. Catriona Kinane (MPH candidate GH 2018)
23. Naomi Patterson (MPH candidate GLEPI 2018)
24. Meghan Peterson (MPH candidate GLEPI 2018)
25. Kanya Rajakopalan (MPH candidate GH 2018)
26. Gilian Smith (MPH candidate Epi 2018)
27. Amy Whitesell (MPH candidate Epi 2018)
28. Yue Zhang (MPH candidate GH 2018)
29. Lillian Chen (MPH candidate GH 2019)
30. Mushtaq Dualeh (MPH candidate, 2019)
31. Natalie La Gattuta (MPH candidate GH 2019)
32. Cynthia Jones (MPH candidate GH 2019)
33. Katherine Milazzo (MPH candidate GH 2019)
34. Jolie Anastasia Siegel (MPH candidate GH 2019)
35. Marina Bruck (MPH candidate EPI 2020)
36. Rebecca castor (MPH candidate, GLEPI 2020)
37. Stephanie O'Connor (MPH candidate GH 2020)
38. Frances Neunuebel (MPH candidate, EPI 2020)
39. Rama V Thyagarajan, MD (MPH candidate, EMPH 2020)
40. Molly Layden (MPH candidate, GH 2021)
41. Christopher Valleau (MPH candidate, GLEPI 2021)
42. Marissa L. Morales, RN, BSN (MPH candidate, GH 2021)
43. Dr. Tarik Rhandour, Hubert H. Humphrey Fellow from Morocco, 2021
44. Dr. Tapiwa Tarumbiswa, Hubert H. Humphrey Fellow from Lesotho, 2021
45. Hanna Amanuel (MPH candidate, GH 2022)
46. Myrna del Mar Gonzalez Montalvo (MPH candidate, GH 2022)

47. Nisha Patel (MPH candidate, GH 2022)
48. Megan Taylor (MPH candidate, GH 2022)
49. Mia Colton (MPH candidate, GH 2023)
50. Okoli, Tiffany (MPH candidate GH - Graduate in Residence 2023)
51. Grube, Steven (EMPH candidate, 2023)
52. Christina Kuo (MPH candidate, GH 2024)
53. Thomas, Zahrya (MPH candidate GH – Graduate in Residence 2024)
54. Coordinator & Advisor, 28<sup>th</sup> Cohort of 13 Emory Humphrey Fellows from 12 countries  
(2021-2022)
55. Director & Advisor, 29<sup>th</sup> Cohort of 11 Emory Humphrey Fellows from 11 countries  
(2022-2023)
56. Director & Advisor, 30<sup>th</sup> Cohort of 11 Emory Humphrey Fellows from 10 countries  
(2023-2024)

## Peer-Reviewed Publications and Book Chapters

1. Best TL, **Castro KG**. A synopsis of Puerto Rican mammals. *Stu Nat Sci* 1981;2:1-12.
2. **Castro KG**. Dengue Fever. *The Hapten-SUNY Stony Brook School of Medicine Newsletter* 1979;3:41-2.
3. **Castro KG**, Hardy AM. Acquired immunodeficiency syndrome (AIDS): epidemiologic and clinical overview. *J Med Assoc GA* 1984;73(8):537-542. PMID: 6481251
4. Chamberland ME, **Castro KG**, Haverkos HW, Miller BI, Thomas PA, Reiss R, Walker J, Spira TJ, Jaffe HW, Curran JW. Acquired immunodeficiency syndrome in the United States: an analysis of cases outside high-incidence groups. *Ann Intern Med* 1984;101(5):617-623. PMID: 6333197
5. Spira TJ, **Castro KG**. The epidemiology of the acquired immunodeficiency syndrome (AIDS). In: Ishikaza K, Kallos P, Lachman PJ, Waksman BH, eds. *Progress in Allergy*. Basel, Switzerland: S. Karger 1986;37:65-80. PMID: 3008169
6. **Castro KG**, Hardy AM, Curran JW. The acquired immunodeficiency syndrome: epidemiology and risk factors for transmission. In: Cooney TG, Ward TT, eds. *AIDS and other medical problems of the male homosexual*. Med Clin North Am. Philadelphia, PA: W.B. Saunders 1986;70(3):635-649. PMID: 3007891
7. Ruttenber AJ, Garbe PL, Kalter HD, **Castro KG**, Tetrud JW, Porter P, Irwin IA, Langston JW. Meperidine analog exposure in California narcotics abusers: initial epidemiologic findings In: Markey SP, Castagnoli N, Trevor M, Kopin IJ, eds. *MPTP: A neurotoxin producing a Parkinsonian Syndrome*. Washington, D.C.: Academic Press 1986;339-353.
8. Lifson AR, **Castro KG**, McCray E, Jaffe HW. National surveillance data of AIDS in health care workers. *JAMA* 1986;256(23):3231-3234. PMID: 3783866
9. The Collaborative Study Group of AIDS in Haitian-Americans (**Castro KG, corresponding author**). Risk factors for HIV/AIDS among Haitians residing in the United States: evidence of heterosexual transmission. *JAMA* 1987;257(5):635-39. PMID: 3795445
10. Lifson AR, **Castro KG**. AIDS cases with "no identified risk." In: Wormser GP, Stahl R, Bottone EJ, eds. *AIDS and Other Manifestations of HIV Infection*. Park Ridge, New Jersey: Noyes Publishers 1987;86-95.

11. **Castro KG**, Lieb S, Jaffe HW, Narkunas JP, Calisher CH, Bush T, Witte JJ, The Belle Glade Field Study Group. Transmission of HIV in Belle Glade, Florida: lessons for other communities in the United States. *Science* 1988;239(4836):193-97. PMID: 3336781
12. **Castro KG**, Lifson AR, White CR, Bush TJ, Chamberland ME, Lekatsas AM, Jaffe HW. Investigations of AIDS patients with no previously identified risk factors. *JAMA* 1988;259(9):1338-42. PMID: 3339838
13. **Castro KG**, Hardy AM, Curran JW. The acquired immunodeficiency syndrome: epidemiology and risk factors for transmission. In: Galea RP, Lewis BF, Baker LA, eds. *AIDS and IV Drug Abusers*. Owings Mills, Maryland: National Health Publishing 1988;25-40.
14. Selik RM, **Castro KG**, Pappaioanou M. Racial/ethnic differences in the risk of AIDS in the United States. *Am J Public Health* 1988;78(12):1539-1545. PMID: 3189630
15. Lifson AR, Chiasson MA, Lekatsas A, Stoneburner R, Chamberland ME, **Castro KG**. Screening for HIV Infection in Sexually Transmitted Disease Clinics (letter). *New Engl J Med* 1988;319(4):242-243.
16. Lieb S, **Castro KG**, Calisher CH, Withum DG, Buff EE, Schable CA, Monath TP, Jaffe HW, Witte JJ. Human immunodeficiency virus in a rural community. *J Fla Med Assoc* 1988;75(5):301-304. PMID: 3385399
17. Calisher CH, Lazuick JS, Lieb S, Monath TP, **Castro KG**. Human infections with Tensaw virus in South Florida: evidence that Tensaw virus subtypes stimulate the production of antibodies reactive with closely related Bunyamwera serogroup viruses. *Am J Trop Med Hyg* 1988;39(1):117-122. PMID: 2899978
18. **Castro KG**, Manoff SB. The epidemiology of AIDS in Hispanic adolescents. In: Quackenbush M, Nelson M, Clark K, eds. *The AIDS Challenge*. Santa Cruz, California: Network Publications 1988;321-31.
19. Selik RM, **Castro KG**, Pappaioanou M. Distribution of AIDS cases, by racial/ethnic group and exposure category, United States, June 1, 1981- July 4, 1988. *MMWR* 1988;37(SS-3):1-10. PMID: 3137446
20. **Castro, KG**. Mosquitoes not a vector in HIV transmission. *Human Sexuality* 1988;22:10.
21. Selik RM, **Castro KG**, Pappaionau M, Buehler JW. Birthplace and the risk of AIDS among Hispanics in the United States. *Am J Public Health* 1989;79(7):836-839. PMID: 2735468
22. Hahn RA, **Castro KG**. The health care status of Latino populations in the U.S.; a brief review. In: Martinez-Maza O, Shin DM, Banks HE, eds. *Latinos and AIDS: A National Strategy Symposium*. Los Angeles, California: CIRID at UCLA 1989;1-7.

23. Avila C, Stetler HC, Sepúlveda J, Dickinson E, **Castro KG**, Ward JW, Romero G, Valdespino JL. The epidemiology of HIV transmission among paid plasma donors, Mexico City, Mexico. *AIDS* 1989;3(10):631-633. PMID: 2512956
24. Rosenblum L, Hadler S, **Castro K**, et al. Heterosexual transmission of hepatitis B virus in Belle Glade, Florida. *J Infect Dis* 1990;161(3):407-411. PMID: 2313121
25. **Castro KG**, Drotman DP. Epidemiologic trends of HIV infection and AIDS in the United States. *AIDS Medical Report* 1990;3:58-62.
26. **Castro KG**. STDs and used condoms (questions and answers). *JAMA* 1990;263(20):2816.
27. Kreiss JK, **Castro KG**. Special considerations for managing suspected human immunodeficiency virus infection and AIDS in patients from developing countries. *J Infect Dis* 1990;162(4):955-960. PMID: 2205654
28. Greenspan A, **Castro KG**. Heterosexual Transmission of HIV Infection. *SIECUS Report* 1990;19:1-8.
29. Dooley SW Jr, **Castro KG**, Hutton MD, Mullan RJ, Polder JA, Snider DE Jr. Guidelines for preventing the transmission of tuberculosis in health-care settings, with special focus on HIV-related issues. *MMWR* 1990;39(RR-17):1-29. PMID: 2175838
30. Vlahov D, Brewer TF, **Castro KG**, Narkunas JP, Salive ME, Ulrich J, Muñoz A. Prevalence of antibody to HIV-1 among entrants to US correctional facilities. *JAMA* 1991;265(9):1129-1132. PMID: 1995998
31. Luft BJ, **Castro KG**. An overview of the problem of toxoplasmosis and pneumocystosis in AIDS in the USA: implication for future therapeutic trials. *Eur J Clin Microbiol Infect Dis* 1991;10(3):178-181. PMID: 2060523
32. **Castro KG**, Polder JA. Management of Occupational Exposure to the Human Immunodeficiency Virus. In: Schochetman G, George JR, eds. *AIDS Testing: Methodology and Management Issues*. New York, New York:Springer-Verlag 1992:197-204.
33. Simonds RJ, Holmberg SD, Hurwitz RL, Coleman TR, Bottenfield S, Conley LJ, Kohlenberg SH, **Castro KG**, Dahan BA, Schable CA, Rayfield MA, Rogers MF. Transmission of human immunodeficiency virus type 1 from a seronegative organ and tissue donor. *New Engl J Med* 1992;326(11):726-732. PMID: 1738377

34. Edlin BR, Tokars JI, Grieco MH, Crawford JT, Williams J, Sordillo EM, Ong KR, Kilburn JO, Dooley SW, **Castro KG**, Jarvis WR, Holmberg SD. An outbreak of multidrug-resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome. *New Engl J Med* 1992;326(23):1514-1521. PMID: 1304721
35. Villarino ME, Dooley SW, Geiter LJ, **Castro KG**, Snider DE. Management of persons exposed to multidrug-resistant tuberculosis. *MMWR* 1992;41(RR-11):59-71
36. Edlin BR, Tokars JI, **Castro KG**, Dooley SW. Multidrug-resistant tuberculosis (letter). *New Engl J Med* 1992;327:1174.
37. **Castro KG**, Dooley SW, Curran JW. Transmission of HIV-associated tuberculosis to health-care workers (letter). *Lancet* 1992;340(8826):1043-1044. PMID: 1357437
38. **Castro KG**, Valdiserri RO, Curran JW. Perspectives on HIV/AIDS epidemiology and prevention from the eighth international conference on AIDS. *Am J Public Health* 1992;82(11):1465-1470. PMID: 1443293
39. **Castro KG**, Dooley SW. Mycobacterium tuberculosis transmission in health-care settings: is it influenced by coinfection with human immunodeficiency virus? *Infect Control Hosp Epidemiol* 1993;14(2):65-66. PMID: 8440881
40. Slutsker L, **Castro KG**, Ward JW, Dooley SW Jr. Epidemiology of extrapulmonary tuberculosis among persons with AIDS in the United States. *Clin Infect Dis* 1993;16(4):513-518. PMID: 8513057
41. Diaz T, Buehler JW, **Castro KG**, Ward JW. AIDS trends among Hispanics in the United States. *Am J Public Health* 1993;83(4):504-509. PMID: 8384802
42. **Castro KG**. Distribution of acquired immunodeficiency syndrome and other sexually transmitted diseases in racial and ethnic populations, United States: influences of life-style and socioeconomic Status. *Ann Epidemiol* 1993;3(2):181-184. PMID: 8269073



43. Fleming PL, Ciesielski CA, Byers RH, **Castro KG**, Berkelman RL. Gender differences in reported AIDS-indicative diagnoses. *J Infect Dis* 1993;168(1):61-67. PMID: 8515133
44. **Castro KG**, Ward JW, Slutsker L, Buehler JW, Jaffe HW, Berkelman RL, Curran JW. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. *Clin Infect Dis* 1993;17:802-810. PMID: 1361652 doi: <https://doi.org/10.1093/clinids/17.4.802>
45. Telzak EE, Chiasson MA, Bevier PJ, Stoneburner RL, **Castro KG**, Jaffe HW. HIV-1 seroconversion in patients with and without genital ulcer disease. *Ann Intern Med* 1993;119(12):1181-1186. PMID: 8239249
46. Villarino ME, Geiter LJ, Schulte JM, **Castro KG**. Purified protein derivative tuberculin and delayed-type hypersensitivity skin testing in migrant farmworkers at risk for tuberculosis and HIV coinfection. *AIDS* 1994;8(4):477-481. PMID: 8011250
47. Murillo J, **Castro KG**. HIV infection and AIDS in Latin America: epidemiologic features and clinical manifestations. In: Isturiz RE, Gotuzzo E, eds. *Diseases of Latin America*. *Inf Dis Clin North Am*. Philadelphia, PA: W.B. Saunders 1994;8(1):1-11. PMID: 8021440
48. Kilbourne BW, Gwinn M, **Castro KG**, Oxtoby MJ. HIV infection and AIDS among women: impact on Hispanic women residing in the United States. In: Lamberty G, Garcia Coll C, eds. *Puerto Rican Women and Children*. New York, NY: Plenum Press 1994:103-117.
49. Bloch AB, Onorato IM, **Castro KG**. Tracking tuberculosis (letter). *JAMA* 1994;272(3):200-201. PMID: 8022033
50. Bloch AB, Sumartojo E, **Castro KG**. Directly observed therapy for tuberculosis in New York City (letter). *JAMA* 1994;272(4):436.
51. Bloch AB, Onorato IM, **Castro KG**. Multiple antibiotic-resistant bacteria (letter). *New Engl J Med* 1994;331(10):678-679. PMID: 8052284
52. Driver CR, Valway SE, Morgan WM, Onorato IM, **Castro KG**. Transmission of *Mycobacterium tuberculosis* associated with air travel. *JAMA* 1994;272(3):1031-1035. PMID: 8089885
53. Rosenblum LS, **Castro KG**, Dooley S, Morgan M. Effect of HIV infection and tuberculosis on hospitalizations and cost of care for young adults in the United States, 1985-1990. *Ann Intern Med* 1994;121(10):786-792. PMID: 7944056

54. Cardo DM, **Castro KG**, Polder JA, Bell DM. Management of Occupational Exposure to HIV. In: Schochetman G, George RJ, eds. AIDS Testing. New York, New York: Springer-Verlag 1994: 361-375.
55. Onorato IM, Kent JH, **Castro KG**. Epidemiology of tuberculosis. In: Lutwick LI, editor, Tuberculosis: a clinical handbook. London, England: Chapman and Hall 1995:20-53.
56. Frieden TR, Simone PM, **Castro KG**. Case 34-1994: laryngeal tuberculosis (letter). *New Engl J Med* 1995;332(9):610. PMID: 7838204
57. Huebner RE, **Castro KG**. The changing face of tuberculosis. In: Coggins CH, Hancock EW, Levitt LJ, editors. Annual Rev Med. Palo Alto, CA: Annual Reviews, Inc. 1995;46:47-55. PMID: 7598480
58. **Castro K**. The adequacy of human immunodeficiency virus and acquired immunodeficiency syndrome data on Puerto Ricans for public health policy developments. In: Menéndez BS, editor. The HIV/AIDS Epidemic in a Commuting Population: Puerto Ricans in New York City and Puerto Rico (Proceedings from the Conference). New York, NY: Lehman College, The City University of New York. 1995:61-65.
59. Critchley SE, **Castro KG**. Management of occupational exposure to HIV. *Seminars in Dermatology* 1995;14(3):235-239. PMID: 7488540
60. **Castro KG**. Tuberculosis as an opportunistic disease in persons infected with the human immunodeficiency virus. *Clin Infect Dis* 1995;21(Suppl 1):S66-71. PMID: 8547515
61. Phair JP, Gross PA, Kaplan JE, Masur H, Holmes KK, Wilfert CM, Martone WJ, **Castro KG**. Quality standard for the identification and treatment of persons coinfectd with human immunodeficiency virus and *Mycobacterium tuberculosis*. *Clin Infect Dis* 1995;21(Suppl 1):S130-131. PMID: 8547505
62. Hu DJ, Fleming PL, **Castro KG**, et al. How important is race/ethnicity as an indicator of risk for specific AIDS-defining conditions? *J Acquir Immune Defic Syndr Hum Retrovirol.* 1995;10(3):374-380. PMID: 7552500
63. **Castro KG**, Snider DE Jr. The good news and the bad news about multidrug-resistant tuberculosis (editorial). *Clin Infect Dis* 1995;21(5):1265-1266. PMID: 8589152
64. Dooley SW, **Castro KG**, Snider DE Jr. Perspectives on the elimination of tuberculosis in the United States. In: Rom WN, Garay SM, editors. Tuberculosis. Boston, Massachusetts: Little, Brown & Co. 1995:973-982.
65. Bevier PJ, Chiasson MA, Hefferman RT, **Castro KG**. Women at a sexually transmitted disease clinic who reported same-sex contact: their HIV seroprevalence and risk behaviors. *Am J Public Health* 1995;85(10):1366-1371. PMID: 7573619

66. Bloch AB, Simone PM, McCray E, **Castro KG**. Preventing multidrug-resistant tuberculosis (editorial). *JAMA* 1996;275(6):487-489. PMID: 8627974
67. **Castro KG**, Blinkhorn RJ Jr, Ellner JJ, Chaisson RE, Horsburgh CR Jr, Masur H, Holmes KK, Kaplan JE. Secondary prophylaxis for tuberculosis in patients infected with human immunodeficiency virus. *Clin Infect Dis* 1996;22:399-400.
68. Kenyon TA, Valway SE, Ihle WW, Onorato IM, **Castro KG**. Transmission of multidrug-resistant *Mycobacterium tuberculosis* during a long airplane flight. *N Engl J Med* 1996;334(15):933-938. PMID: 8596593
69. McCombs SB, Onorato IM, McCray E, **Castro KG**. Tuberculosis surveillance in the United States: case definition used by state health departments. *Am J Public Health* 1996;86(5):728-730. PMID: 8629728
70. Cauthen GM, Dooley SW, Onorato IM, Ihle WW, Burr JM, Bigler WJ, Witte J, **Castro KG**. Transmission of *Mycobacterium tuberculosis* from tuberculosis patients with HIV infection or AIDS. *Amer J Epidemiol* 1996;144(1):69-77. PMID: 8659487
71. Villarino ME, Simone PM, McCray E, Bloch AB, **Castro KG**. Preventive therapy for multigrug-resistant tuberculosis (letter). *JAMA* 1996;276(1):28.
72. De Cock KM, Binkin NJ, Zuber PLF, Tappero JW, **Castro KG**. Research issues involving HIV-associated tuberculosis in resource-poor countries. *JAMA* 1996;276(18):1502-1507. PMID: 8903262
73. Binkin NJ, Zuber PLF, Wells CD, Tipple MA, **Castro KG**. Overseas screening of tuberculosis in immigrants and refugees to the United States: current status. *Clin Infect Dis* 1996;23(6):1226-1232. PMID: 8953062
74. Miller B, **Castro KG**. Sharpen available tools for tuberculosis control, but new tools needed for elimination (editorial). *JAMA* 1996;276(23):1916-1917. PMID: 8968019
75. Braden CR, Templeton GL, Cave MD, Valway S, Onorato IM, **Castro KG**, Moers D, Yang Z, Stead WW, Bates JH. Interpretation of restriction fragment length polymorphism analysis of *Mycobacterium tuberculosis* isolates from a state with a large rural population. *J Infect Dis* 1997;175(6):1446-1452. PMID: 9180185

76. Kenyon TA, Ridzon R, Luskin-Hawk R, Schultz C, Paul WS, Valway SE, Onorato IM, **Castro K**. Nosocomial outbreak of multidrug-resistant tuberculosis. *Ann Intern Med* 1997;127(1):32-36. PMID: 9214250
77. Zuber PLF, McKenna MT, Binkin NJ, Onorato IM, **Castro KG**. Long-term risk of tuberculosis among foreign-born persons in the United States. *JAMA* 1997;278(4):304-307. PMID: 9228436
78. Simone PM, Horsburgh CR, **Castro KG**. Antimycobacterial drugs. In: Gorbach SL, Bartlett JG, Blacklow NR, eds. *Infectious Diseases*, 2nd edition. Philadelphia, Pennsylvania:W. B. Saunders Company 1997:359-376.
79. Moore M, Onorato IM, McCray E, **Castro KG**. Trends in drug-resistant tuberculosis in the United States, 1993-1996. *JAMA* 1997;278(10):833-837. PMID: 9293991
80. **Castro KG**. Recommendations for rifampin and protease inhibitor treatment of tuberculosis and human immunodeficiency virus infection. In: Casal M, ed. *Clinical Mycobacteriology*. Barcelona, Spain: Prous Science, S.A. 1998:343-349.
81. Snider DE Jr, **Castro KG**. The global threat of drug-resistant tuberculosis (editorial). *New Engl J Med* 1998;338(23):1689-1690. PMID: 9614262
82. McKenna MT, McCray E, Jones JL, Onorato IM, **Castro KG**. The fall after the rise: tuberculosis in the United States, 1991 through 1994. *Am J Publ Health* 1998;88(7):1059-1063. PMID: 9663154
83. **Castro KG**. Global tuberculosis challenges. *Emerg Infect Dis*. 1998;4(3):408-409. PMID: 9716957
82. Miller B, Rosenbaum S, Stange PV, Solomon SL, **Castro KG**. Tuberculosis control in a changing health care system: model contract specifications for managed care organizations. *Clin Infect Dis* 1998;27(4):677-686. PMID: 9798014
83. Bloch AB, Cauthen GM, Simone PM, Kelly GD, Dansbury KG, **Castro KG**. Completion of tuberculosis therapy for patients reported in the United States in 1993. *Int J Tuberc Lung Dis* 1999;3(4):273-280. PMID: 10206496
84. Binkin NJ, Vernon AA, Simone PM, McCray E, Miller MI, Schieffelbein CW, **Castro KG**. Tuberculosis prevention and control activities in the United States: an overview of the organization of tuberculosis services. *Int J Tuberc Lung Dis* 1999;3(8):663-674. PMID: 10460098
85. Granich RM, Balandrano S, Santaella AJ, Binkin NJ, **Castro KG**, Marquez-Fiol, Anzaldo G, Zarate M, Jaimes ML, Velazquez-Monroy O, Salazar L, Alvarez-Lucas C, Kuri P, Flisser A, Santos-Preciado J, Ruiz-Matus C, Tapia-Conyer R, Tappero JW. Survey of drug resistance of *Mycobacterium tuberculosis* in 3 Mexican states, 1997. *Arch Intern Med* 2000;160(5):639-644. PMID: 10724049

86. **Castro KG.** [AIDS and Tuberculosis in the United States] SIDA-TBC en EEUU. *Enfermedades Emergentes* 2001;3:135-136 (Spanish publication).
87. Reichler M, Taylor Z, **Castro KG.** Factors in tuberculosis contact investigations (letter). *JAMA* 2002;287(22):2944. PMID: 12052120
88. Ijaz K, **Castro KG.** Pediatric tuberculosis: all in the family? [Editorial] *Infection Control & Hospital Epidemiology* 2002;23(10):562-563. PMID: 12400882
89. Spradling P, Drociuk D, McLaughlin S, Lee LM, Peloquin CA, Gallicano K, Pozsik C, Onorato I, **Castro KG,** Ridzon R. Drug-drug interactions in inmates treated for human immunodeficiency virus and Mycobacterium tuberculosis infection or disease: an institutional tuberculosis outbreak. *Clin Infect Dis* 2002;35(9):1106-1112. PMID: 12384845
90. **Castro KG.** Jaffe HW. Rationale and methods for the National Tuberculosis Genotyping and Surveillance Network. *Emerg Infect Dis* 2002;8(11):1188-1191. PMID: 12453341
91. Schneider E. **Castro KG.** Tuberculosis trends in the United States, 1992-2001. *Tuberculosis* 2003;83(1-3):21-29. PMID: 12758185
92. **Castro KG.** Jereb JA. Koppaka VR. Cohn DL. Fatal liver injury associated with rifampin-pyrazinamide treatment of latent tuberculosis infection. *Chest* 2003;123(3):967. PMID: 12628913
93. **Castro KG,** Villarino EM. [Studies for the treatment of latent tuberculosis infection in the United States]. *Estudios para el tratamiento de la infección tuberculosa latente en Estados Unidos.* *Enfermedades Emergentes* 2003;5:228-229 (Spanish publication).
94. Reichler MR, Etkind S, Taylor Z, **Castro KG** (guest editors). Tuberculosis Contact Investigations Supplement. *Int J Tuberc Lung Dis* 2003 (12 Suppl);7:S325-S516.
95. Reichler MR, Etkind S, Taylor Z, **Castro KG.** Tuberculosis contact investigations (editorial). *Int J Tuberc Lung Dis* 2003;7(12 Suppl):S325-S327. PMID: 14677816
96. Reichler MR, Bur S, Reves R, Mangura B, Thompson V, Ford J, **Castro KG.** Results of testing for human immunodeficiency virus infection among recent contacts of infectious tuberculosis cases in the United States. *Int J Tuberc Lung Dis* 2003;7(12 Suppl):S471-S478. PMID: 14677840

97. Iademarco MF, **Castro KG**. Epidemiology of tuberculosis. *Semin Respir Infect*. 2003;18(4):225-240. PMID: 14679472
98. Koppaka VR, Horsburgh CR, **Castro KG**. Chapter 34. Antimycobacterial drugs. In: Gorbach SL, Bartlett JG Blacklow NR, editors. *Infectious Diseases (Third Edition)*. Philadelphia, PA: Lippincott Williams & Wilkins 2004:328-344.
99. Horsburgh CR, Moore M, **Castro KG**. Epidemiology of tuberculosis in the United States. In: Rom WN, Garay SM, editors. *Tuberculosis (Second edition)*. Philadelphia, PA: Lippincott Williams & Wilkins 2004:31-45.
100. Iademarco MF, **Castro KG**. Tuberculosis elimination in the United States. In: Rom WN, Garay SM, editors. *Tuberculosis (Second edition)*. Philadelphia, PA: Lippincott Williams & Wilkins 2004:899-907.
101. Jereb J, Albalak R, **Castro KG**. The Arden House Conference on tuberculosis, revisited: perspectives for tuberculosis elimination in the United States. *Semin Resp Crit Care Med* 2004;25(3):255-269. PMID: 16088468
102. Nelson LJ, Jereb JA, **Castro KG**. New guidelines about latent tuberculosis infection in children and adolescents: a welcome advancement. *Pediatrics* 2004;114(4):1084-1086. PMID: 15466109
103. Costamagna P, Furst K, Tully K, Landis J, Moser K, Quach L, Kwak J, Calvet H, Lindsey B, Flood J, Braun M, Winthrop K, Jereb J, Taylor Z, Iademarco M, **Castro K**. Tuberculosis associated with blocking agents against tumor necrosis factor- $\alpha$  --- California, 2002—2003. *MMWR* 2004;53(30):680-686
104. **Castro KG**. The return of the White Plague; global poverty and the 'new' tuberculosis (Book Review). *N Engl J Med* 2004;351:2665-2666.
105. Schneider E, Moore M, **Castro KG**. Epidemiology of tuberculosis in the United States. *Clin Chest Med* 2005;26(2):183-195. PMID: 15837104
106. McElroy PD, Ijaz K, Lambert LA, Jereb JA, Iademarco MF, **Castro KG**, Navin TR. National survey to measure rates of liver injury, hospitalization, and death associated with rifampin and pyrazinamide for latent tuberculosis infection. *Clin Infect Dis* 2005;41(8):1125-1133. PMID: 16163632
107. Ijaz K, Jereb JA, Lambert LA, Bower, WA, Spradling PR, McElroy PD, Iademarco MF, Navin TR, **Castro KG**. Severe or fatal liver injury in 50 patients in the United States taking rifampin and pyrazinamide for latent tuberculosis infection. *Clin Infect Dis* 2006;42(3):346-355. PMID: 16392079

108. Jereb JA, Nelson LJ, **Castro KG**. Commentary on the risk of active tuberculosis. *Arch Pediatr Adolesc Med* 2006;160(3):317-318. PMID: 16520453
109. Lobato MN, Wang YC, Becerra JE, Simone PM, **Castro KG**. Improved program activities are associated with decreasing tuberculosis incidence in the United States. *Publ Health Reports* 2006;121(2):108-115. PMID: 16528941
110. Reid A, Scano F, Getahun H, Williams B, Dye C, Nunn P, De Cock KM, Hankins C, Miller B, **Castro KG**, Raviglione MC. Towards universal access to HIV prevention, treatment, care, and support: the role of tuberculosis/HIV collaboration. *Lancet Infect Dis* 2006;6(8):483-495. PMID: 16870527
111. Iademarco MF, **Castro KG**. Chapter 30. Tuberculosis in the United States: toward elimination? In: Raviglione, editor. *Reichman and Hershfield's Tuberculosis: a comprehensive, international approach (Third Edition)*. New York, NY: Informa Healthcare USA, Inc. 2006:767-792.
112. Cain KP, Haley CA, Armstrong LR, Garman KN, Wells CD, Iademarco MF, **Castro KG**, Laserson KF. Tuberculosis among foreign-born persons in the United States: achieving tuberculosis elimination. *Am J Respir Crit Care Med* 2007;175(1):75-79. PMID: 17038659
113. Ijaz K, McElroy PD, Jereb J, Navin TR, **Castro KG**. Safety of the rifampin and pyrazinamide short-course regimen for treating latent tuberculosis infection. *Clin Infect Dis* 2007;44(3):464-465. PMID: 17205462
114. **Castro KG**. Tuberculosis surveillance: data for decision-making. *Clin Infect Dis*. 2007;44(10):1268-70. PMID: 17443461
115. Wells CD, Cegielski JP, Nelson LJ, Laserson KF, Holtz TH, Finlay A, **Castro KG**, Weyer K. HIV Infection and multidrug-resistant tuberculosis - the perfect storm. *J Infect Dis* 2007;196(Suppl 1):S86-S107. PMID: 17624830
116. Albalak R, O'Brien RJ, Kammerer JS, O'Brien SM, Marks SM, **Castro, KG**, Moore M. Trends in tuberculosis/human immunodeficiency virus comorbidity, United States, 1993-2004. *Arch Intern Med* 2007;167(22):2443-2452. PMID: 18071166

117. Cetron M, **Castro KG**. Protecting the public's health against tuberculosis: moving forward. *J Med Assoc GA* 2007;96(2):30. PMID: 18019445
118. Mitnick CD, **Castro KG**, Harrington M, Sacks LV, Burman W. Randomized trials to optimize treatment of multidrug-resistant tuberculosis. *PLoS Medicine* 2007;4(11):1730-1734. PMID: 17988168
119. Bennett DE, Courval JM, Onorato I, Agerton T, Gibson JD, Lambert L, McQuillan GM, Lewis B, Navin TR, **Castro KG**. Prevalence of tuberculosis infection in the United States population: the national health and nutrition examination survey, 1999-2000. *Am J Respir Crit Care Med* 2008;177(3):348-355. PMID: 17989346
120. LoBue PA, Iademarco MF, **Castro KG**. The epidemiology, prevention, and control of tuberculosis in the United States. In: Fishman AP, Elias JA, Fishman JA, Grippi MA, Senior RM, Pack AI, editors. *Fishman's Pulmonary Disease and Disorders (Fourth edition)*. New York, NY: McGraw-Hill 2008:2447-2457.
121. Khan K, Navin TR, Courval JM, Bierman A, Bennett DE, **Castro KG**, Gardam M. Decline in prevalence of latent tuberculosis infection: is the waning of tuberculin reaction a factor? (Correspondence) *Am J Respir Crit Care Med* 2008;178:652-653.
122. Cain KP, Mac Kenzie WR, **Castro KG**, LoBue PA. No man is an island: reducing diagnostic delays in undocumented foreign-born persons is needed to decrease the risk of tuberculosis transmission. *Clin Infect Dis* 2008;47(10):1285-1286. PMID: 18834316
123. Shah NS, Pratt R, Armstrong L, Robison V, **Castro KG**, Cegielski JP. Extensively drug-resistant tuberculosis in the United States, 1993-2007. *JAMA* 2008;300(18):2153-2160. PMID: 19001626
124. LoBue P, Sizemore C, **Castro KG**. Plan to combat extensively drug-resistant tuberculosis: recommendations of the Federal Tuberculosis Task Force. *MMWR* 2009;58(RR-3):1-43.
125. Lobato MN, Jereb JA, **Castro KG**. Do we have evidence for policy changes in the treatment of children with latent tuberculosis infection? *Pediatrics* 2009;123(3):902-903. PMID: 19255018



126. **Castro KG**, Bell BP, Schuchat A. Preventing complications from 2009 influenza A (H1N1) in persons with underlying lung diseases: a formidable challenge for 2010 Year of the Lung. *Int J TB Lung Dis* 2010;14(2):127-129. PMID: 20074400
127. Lönnroth K, **Castro KG**, Chakaya JM, Chauhan LS, Floyd K, Glaziou P, Raviglione MC. Tuberculosis control and elimination 2010-50: cure, care, and social development. *Lancet* 2010;375(9728):1814-1829. PMID: 20488524
128. Mazurek GH, Jereb J, Vernon A, LoBue P, Goldberg S, **Castro K**. Updated guidelines for using interferon gamma release assays to detect *Mycobacterium tuberculosis* infection – United States, 2010. *MMWR* 2010;59(RR-5):1-25.
129. **Castro KG**, LoBue P. Bridging implementation, knowledge, and ambition gaps to eliminate tuberculosis in the United States and globally. *Emerg Infect Dis* 2011;17(3):337-342. PMID: 21392421
130. Samandari T, Agizew TB, Nyirenda S, Tedia Z, Sibanda T, Shang N, Mosimaneotsile B, Motsamai OI, Bozeman L, Davis MK, Talbot EA, Moeti TL, Moffat HJ, Kilmarx PH, **Castro KG**, Wells CD. 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial. *Lancet* 2011;377(9777):1588-1598. [Epub ahead of print April 12, 2011]. PMID: 21492926
131. **Castro KG**, Cohn DL, Burman WJ, Reves RR, Iseman MD. John A. Sbarbaro, 1936–2011, Obituary. *Int J TB Lung Dis* 2011;15(11):1562
132. Winston CA, Navin TR, Becerra JE, Chen MP, Armstrong LR, Jeffries C, Yelk Woodruff RS, Wing J, Starks AM, Hales C, Kammerer JS, Mac Kenzie WR, Mitruka K, Miner MC, Price S, Scavotto J, Cronin AM, Griffin P, LoBue PA, **Castro KG**. Unexpected decline in tuberculosis cases coincident with economic recession – United States, 2009. *BMC Public Health* 2011;11:846 (pages 1-12) doi:10.1186/1471-2458-11-846 [Epub ahead of print]. PMID: 22059421
133. Hadler SC, **Castro KG**, Dowdle W, Hicks L, Noble G, Ridzon R. Epidemic Intelligence Service investigations of respiratory illness, 1945-2005. *Am J Epidemiol* 2011;174(11 Suppl.):S36-S46. doi: 10.1093/aje/kwr309. PMID: 22135392
134. Hill AN, Becerra JE, **Castro KG**. Modelling tuberculosis trends in the USA. *Epidemiol Infect.* 2012;140(10):1862-1872. [Epub ahead of print January 11, 2012]. PMID: 22233605
135. Zachariah R, Ford N, Maher D, Bissell K, Van den Bergh R, van den Boogaard W, Reid T, **Castro KG**, Draguez B, von Schreeb J, Chakaya J, Atun R, Lienhart C, Enarson DA, Harries AD. Is operational research delivering the goods? The journey to success in low-income countries. *Lancet Infect Dis* 2012;12(5):415-421. [Epub ahead of print February 9, 2012: 1-7]. doi:10.1016/S1473-3099(11)70309-7. PMID: 22326018

136. LoBue PA, **Castro KG**. Is it time to replace the tuberculin skin test with a blood test? (Viewpoint) *JAMA* 2012;308(3):241-242. doi: 10.1001/jama.2012.7511. PMID: 22797639
137. Cegielski P, Nunn P, Kurbatova EV, Weyer K, Dalton TL, Wares DF, Iademarco MF, **Castro KG**, Raviglione M. Challenges and controversies in defining totally drug-resistant tuberculosis. *Emerg Infect Dis*. 2012 Nov;18(11):e2. doi:10.3201/eid1811.120526. Published online September 26, 2012. <http://dx.doi.org/10.3201/eid1811.120526>. PMID: 23092736
138. Mase S, Chorba T, LoBue P, **Castro K**. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis. *MMWR* 2013;62(RR-9):1-12.
139. Shinnick TM, Starks AM, Alexander H, **Castro KG**. Evaluation of the Cepheid Xpert® MTB/RIF Assay. *Expert Rev Mol Diagn*. 2015 Jan;15(1):9-22. doi: 10.1586/14737159.2015.976556. [Epub 2014 Nov 6]. PMID: 25373876.
140. Moore BK, Posey DL, Maloney SA, Cetron M, **Castro K**. Tackling Tuberculosis Abroad: the Key to TB Elimination in the United States. Center for Strategic & International Studies. A Report of the Global Health Policy Center, Center for Strategic and International Studies 2014 June ([http://csis.org/files/publication/140604\\_Moore\\_TacklingTBAbroad\\_Web.pdf](http://csis.org/files/publication/140604_Moore_TacklingTBAbroad_Web.pdf))
141. Villarino ME, Scott NA, Weis SE, Weiner M, Conde MB, Jones B, Nachman S, Oliveira R, Moro RN, Shang N, Goldberg SV, Sterling TR; International Maternal Pediatric and Adolescents AIDS Clinical Trials Group; Tuberculosis Trials Consortium (**Castro KG** – collaborator). Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid. *JAMA Pediatr*. <https://www.ncbi.nlm.nih.gov/pubmed/25580725> 2015;169(3):247-55. doi: 10.1001/jamapediatrics.2014.3158
142. Miramontes R, Hill AN, Yelk Woodruff RS, Lambert LA, Navin TR, **Castro KG**, LoBue PA. Tuberculosis infection in the United States: prevalence estimates from the National Health and Nutrition Examination Survey, 2011-2012. *PLOS ONE* 2015;10(11):e0140881. doi:10.1371/journal.pone.0140881. PMID: 26536035.
143. **Castro KG**, Marks SM, Chen MP, Hill AN, Becerra JE, Miramontes R, Winston CA, Navin T, Pratt RH, Young KH, LoBue PA. Estimating tuberculosis cases and their economic costs averted in the United States over the past two decades. *Int J Tuberc Lung Dis* 2016;20(7):926-933. doi:10.5588/ijtld.15.1001. PMID: 27287646.
144. Colvin CE, **Castro KG**. Measurement of TB disease burden in Tanzania through a population based survey: merits and limitations. (Editorial). *Int J Tuberc Lung Dis* 2016;20(8):995. doi:10.5588/ijtld.16.0368. PMID: 27393527.

145. **Castro KG**. Detection and treatment of persons with latent tuberculosis infection: bridging the policy to practice gap (Editorial). *Int J Tuberc Lung Dis* 2016; 20(12):1565. PMID: 27931329.
146. **Castro KG**, Marks SM, Hill AN, Chen M, Miramontes R, Winston CA, LoBue PA. The cost of the failure to eliminate tuberculosis in the United States (Correspondence). *Int J Tuberc Lung Dis* 2017;21(1):120-121. doi: 10.5588/ijtld.16.0708-2. PMID: PMC5428887
147. Bayer R, **Castro KG**. Tuberculosis elimination in the United States – the need for renewed action. *N Engl J Med* 2017;377(12):1109-1111. doi: 10.1056/NEJMp1707387. PMID: 28930506.
148. Marais BJ, Walker TM, Cirillo DM, Raviglione M, Abubakar I, van der Werf MJ, Boehme C, Niemann S, **Castro KG**, Zumla A, Sintchenko V, Crook DW. Aiming for zero tuberculosis transmission in low-burden countries. *Lancet Respir Med* 2017;5(11):846-848. doi: 10.1016/S2213-2600(17)30382-X. PMID: 29033268.
149. **Castro KG**, Evans DE, Del Rio C, Curran JW. Seven Deadly Sins Resulting From the Centers for Disease Control and Prevention's Seven Forbidden Words. *Ann Intern Med* [Epub ahead of print 9 January 2018] doi: 10.7326/M17-3410. PMID: 29310140.
150. **Castro KG**, Colvin CE. Updated global tuberculosis targets: a welcome ambition in need of attention to quality of care (Editorial). *Int J Tuberc Lung Dis* 2018;22(7):709. doi: 10.5588/ijtld.18.0344. PMID: 29914592
151. Alqahtani S, Kashkary A, Asiri A, Kamal H, Binongo J, **Castro K**, McNabb S. Impact of mobile teams on tuberculosis treatment outcomes, Riyadh Region, Kingdom of Saudi Arabia, 2013-2015. *J Epidemiol Glob Health*. 2018;Suppl 1:S29-S33. doi: 10.1016/j.jegh.2017.09.005. PMID: 29801590
152. Haddad MB, Raz KM, Lash TL, Hill AN, Kammerer JS, Winston CA, **Castro KG**, Gandhi NR, Navin TR. Simple estimates for local prevalence of latent tuberculosis infection, United States, 2011-2015. *Emerg Infect Dis*. 2018;24(10):1930-1933. doi: <https://dx.doi.org/10.3201/eid2410.180716> PMID: 30226174
153. Haddad MB, Raz KM, Hill AN, Navin TR, **Castro KG**, Winston CA, Gandhi NR, Lash TL. Influence of county sampling on past estimates of latent tuberculosis infection prevalence. *Annals American Thoracic Society* 2019;16(8):1069-1071 (Epub ahead of print) doi: <https://doi.org/10.1513/AnnalsATS.201901-062RL> PMID: 30888833
154. **Castro KG**. Overcoming prevailing neglect to prevent transmission of Mycobacterium tuberculosis infection in healthcare facilities. *Int J Tuberc Lung Dis* 2019;23(4):383-384 doi: <https://doi.org/10.5588/ijtld.19.0179> PMID: 31064615
155. Ridzon R, **Castro KG**. A step forward in the treatment of people with multidrug resistant tuberculosis. *Int J TB Lung Dis* 2019;23(5):533-534 doi: <https://doi.org/10.5588/ijtld.19.0208> PMID: 31097059

156. Mase SR, Samron R, Ashkin D, **Castro KG**, Ryan S, Seaworth B, Chen L, Lardizabal A, Tuckey D, Khan A, Posey DL, Chappelle, Temesgen Z. Tuberculosis Regional Training and Medical Consultation Centers in the United States: Characteristics, Outcomes, and Quality of Medical Consultations, June 1, 2010 – May 31, 2014. *J Clin Tuberc Other Mycobact Dis* 2019;17:100114 doi: <https://doi.org/10.1016/j.jctube.2019.100114> PMID: 31788557
157. Jordan AM, Podewils LJ, **Castro KG**, Zishir V, Chalambous S. Prevalence and risk factors of tuberculosis disease in South African correctional facilities in 2015. *Int J Tuberc Lung Dis* 2019;23(11):1198-1204 doi: <https://doi.org/10.5588/ijtld.18.0782> PMID: 31718756
158. Haddad MB, Lash TL, Hill AN, Navin TR, **Castro KG**, Gandhi NR, Winston CA. Robustness of NHANES Estimates of the U.S. Prevalence of a Positive Tuberculin Skin Test. *Epidemiology* 2020;31(2):248-258 doi: <https://doi.org/10.1097/EDE.0000000000001141> PMID: 31764278
159. Haddad MB, Lash TL, Hill AN, Navin TR, **Castro KG**, Gandhi NR, Magee MJ. Diabetes and latent tuberculosis infection in the United States: heterogeneity by race/ethnicity. *Amer J Prevent Med* 2020;58(6):858-863 doi: <https://doi.org/10.1016/j.amepre.2019.12.010>
160. O'son L, Hulland E, Cookson ST, **Castro KG**, Yaacoub H. Epidemiology and risk factors for extrapulmonary tuberculosis in Lebanon. *Int J Tuberc Lung Dis* 2020;24(4):414-419 doi: <https://doi.org/10.5588/ijtld.19.0523> PMID: 32317066
161. **Castro KG**. The World Health Organization and the U.S.: A brief history of collaboration. *Science Speaks: Global ID News* June 4, 2020 Guest Blog (Available at <https://sciencespeaksblog.org/2020/06/04/the-world-health-organization-and-the-u-s-a-brief-history-of-collaboration/>)
162. Bayer R, Fairchild AL, Zignol M, **Castro KG**. Tuberculosis surveillance and its discontents: the ethical paradox. *Int J Tuberc Lung Dis* 2020;24(s1):9–14 doi: <https://doi.org/10.5588/ijtld.17.0844>
163. Stevenson KA, Podewils LJ, Zishiri VK, **Castro KG**, Charalambous S. HIV prevalence and the cascade of care in five South African correctional facilities. *PLOS ONE* 2020;15(7): e0235178. doi: <https://doi.org/10.1371/journal.pone.0235178>
164. Valencia M, Becerra JE, Reyes J, **Castro KG**. Assessment of Early Mitigation Measures Against COVID-19 in Puerto Rico: March 15-May 15, 2020. *PLoS ONE* 15(10): e0240013. doi: <https://doi.org/10.1371/journal.pone.0240013>
165. Cox H, Shah NS, **Castro KG**. Discovering a new drug is only the beginning: progress and challenges in expanding access to bedaquiline for treatment of rifampicin-resistant and multidrug-resistant tuberculosis. *Int J TB Lung Dis* 2020;24(10):985-986 doi: <https://doi.org/10.5588/ijtld.20.0562>

166. Hopewell PC, Reichman LB, **Castro KG**. Parallels and mutual lessons in tuberculosis and COVID-19 transmission, prevention, and control. *Emerg Infect Dis* 2021;27(3):681-686. doi: <https://doi.org/10.3201/eid2703.203456>) PMID: 33213689
167. Brijkumar J, Johnson BA, Zhao Y, Edwards J, Moodley P, Pathan K, Pillay S, **Castro KG**, Sunpath H, Kuritzkes DR, Moosa MYS, Marconi VC. A packaged intervention to improve viral load monitoring within a deeply rural health district of South Africa. *BMC Infect Dis*. 2020 Nov 11;20(1):836. doi: 10.1186/s12879-020-05576-5. PMID: 33176715
168. Katrak S, Li R, Reynolds S, Marks SM, Probst JR, Chorba T, Winthrop K, **Castro KG**, Goswami ND. Association of Tumor Necrosis Factor  $\alpha$  Inhibitor Use with Diagnostic Features and Mortality of Tuberculosis in the United States, 2010–2017. *Open Forum Infectious Diseases* 2022;9(2), ofab641. <https://doi.org/10.1093/ofid/ofab641>. PMID: 35106318
169. Kyaw NTT, Kumar AMV, Harries AD, Satyanarayana S, Oo NL, Hayat MJ, **Castro KG**, Magee MJ. Synergy between low BMI and hyperglycemia at baseline increases tuberculosis incidence among people living with HIV. *AIDS* 2022;36(1):117-125. doi: <https://doi.org/10.1097/QAD.0000000000003090>. PMID: 34586087
170. Ntoumi F, Nachenga JB, Aklillu E, Chakaya J, Felker I, Amanullah F, Yeboah-Manu D, **Castro KG**, Zumla A. World Tuberculosis Day 2022: aligning COVID-19 and tuberculosis innovations to save lives and to end tuberculosis. *Lancet Infectious Diseases*. 2022 March. doi: 10.1016/S1473-3099(22)00142-6.
171. **Castro KG**, Ditiu L, Sahu S, Ntoumi F, Tiberi S, O’Kane CM, Akkerman O, Manika K, Mwaba P, Davies Forsman L, Petersen E, Aklillu E, Azhar EI, Cirillo DM, Migliori G, Abbara A, Zumla A. Optimising tuberculosis care for refugees affected by armed conflicts. *Lancet Respiratory Medicine*. 2022 March. doi: 10.1016/S2213-2600(22)00104-7.
172. **Castro KG**, Caylá JA. Rifapentine’s long and winding road to European patients. *Enfermedades Emergentes*. 2022 November; 21(3):157-159.
173. Kyaw NTT, Satyanarayana S, Harries AD, Kumar AMV, Kyaw K WY, Phyo KH, Hayat MJ, **Castro KG**, Magee MJ. Increased All-cause Mortality in People With HIV and Comorbidities: Hepatitis B and C Virus Seropositivity and Hyperglycemia in Myanmar, 2005-2017. *Open Forum Infect Dis*. 2023 Jan;10(1):ofac672. doi: <https://doi.org/10.1093/ofid/ofac672>. eCollection 2023 Jan. PMID: 36632421
174. Graciaa DS, Schechter MC, Fetalvero KB, Cranmer LM, Kempker RR, **Castro KG**. Updated considerations in the diagnosis and management of tuberculosis infection and disease: integrating the latest evidence-based strategies. *Expert Rev Anti Infect Ther*. 2023 Jun;21(6):595-616. doi: <https://doi.org/10.1080/14787210.2023.2207820>. PMID: 37128947

175. **Castro KG**, Shah NS. Beyond the bacillus: Closing gaps in TB health disparities requires targeting social determinants. *Ann Intern Med.* 2024 (published at *Annals.org* on 2 April 2024. <https://doi.org/10.7326/M24-0548>)
176. Marco MH, Ahmedov S, **Castro KG**. The Global Impact of COVID-19 on Tuberculosis: A Thematic Scoping Review, 2020-2023 (Submitted for publication in *PLOS GPH*. doi: <https://doi.org/10.1101/2024.03.04.24303743>)

**Other Selected Reports/Policy Guidelines**

1. **Castro KG**. Role of Pentamidine isethionate requests in AIDS Surveillance. Surveillance Report, Epidemic Intelligence Service, Epidemiology Program Office. Fall, 1983.
2. CDC. Update: evaluation of human T-lymphotropic virus type III/lymphadenopathy-associated virus infection in health-care personnel. *MMWR* 1985;34:575-8.
3. CDC. Acquired immunodeficiency syndrome (AIDS) in western Palm Beach County, Florida. *MMWR* 1986;35:609-12.
4. CDC. Public Health Service statement on management of occupational exposure to human immunodeficiency virus (HIV), including considerations regarding Zidovudine postexposure use. *MMWR* 1990;39(No. RR-1):1-14.
5. CDC. Nosocomial transmission of multidrug-resistant tuberculosis among HIV-infected persons- Florida and New York, 1988-1991. *MMWR* 1991;40:585-91.
6. CDC. Update: CD4+ T-lymphocytopenia in persons without evident HIV infection - United States. *MMWR* 1992;41:578-579.
7. CDC. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. *MMWR* 1992;41(No. RR-17):1-19.
8. CDC. Expanded tuberculosis surveillance and tuberculosis morbidity- United States, 1993. *MMWR* 1994;43:361-366.
9. CDC. Notice to readers: recall of isoniazid used for antimicrobial drug susceptibility testing for tuberculosis. *MMWR* 2000;49:780-782.
10. Stop TB Partnership. The global plan to stop tuberculosis. WHO/CDS/STB/2001.16.
11. Burman WJ, Koppaka VR, Gordin F, **Castro KG**. Therapy for tuberculosis. IDSA and USPHS guidelines for therapy of HIV-associated opportunistic infection (2004 update).



12. Global Plan to Stop TB 2006-2015. WHO/HTM/STB/2006.35.
13. Notice to readers: Revised definition of extensively drug-resistant tuberculosis. MMWR 2006;55:1176.
14. Turning the Tide on HIV: Division of HIV/AIDS Prevention Annual Report 2013. ([http://www.cdc.gov/hiv/pdf/policies\\_DHAP\\_AnnualReport\\_2013.pdf](http://www.cdc.gov/hiv/pdf/policies_DHAP_AnnualReport_2013.pdf))
15. Singh, Raj Mohan and **Kenneth G. Castro**. Rapid assessment of the technical support network provided by the World health Organization to the Revised National Tuberculosis Control Programme in India. Health Finance & Governance Project, Abt Associates Inc, Bethesda, MD. August 2016 ([http://origin.searo.who.int/india/tuberculosis/topic/rapid\\_assessment\\_rntcp.pdf](http://origin.searo.who.int/india/tuberculosis/topic/rapid_assessment_rntcp.pdf))
16. Evans DE, **Castro KG**. The CDC's word ban list is harmful to the health of the American public. The Hill (Opinion). December 20, 2017 (<http://thehill.com/opinion/healthcare/365814-the-cdcs-word-ban-list-is-harmful-to-the-health-of-the-american-public>)
17. Becerra JE, Rullan J, **Castro KG**. “The deaths due to Maria claim” (translated title of Spanish op-ed “Las muertes de María reclaman”) published in “Tribuna Invitada.” El Nuevo Dia. August 30, 2018). (<https://www.elnuevodia.com/opinion/columnas/lasmuertesdemariareclaman-columna-2444185/>)
18. **Castro K** (Lead Author), Piatek A, Baddeley A, Bhatnagar A, Bhargava A, Kanchar A, Venkatraman A, Kumar B, Shah D, Faizan D, Reddy DCS, Weil D, Wares DF, Rade K, Sadasivan LS, Chauhan LS, Parmar M, Jain M, Grossman M, Monsicat M, Yassin M, Sharna M, Wilson N, Moonan P, Dewan P, Prasad R, Solanki R, Ramachandran R, Gupta Lawrence R, Cunliffe R, Sarin R, Mutasa R, Singla R, Sharma S, Kebede S, Sharma SK, Nair SA, Sahu S, Shinnick T, SinghU, Singh V, Wells, W, LO W, Mundane Y, World Health Organization (WHO) Country Office (WCO) for India, Central Tuberculosis Division (CTD). 2019 Report of the Joint Monitoring Mission for the Revised National Tuberculosis Control Programme (RNTCP) India. (<https://tbcindia.gov.in/showfile.php?lid=3536>)
19. **Castro KG**. Update: Tuberculosis contact investigations and use of shortened preventive therapy regimens. (Spanish publication: “Actualización: estudio de contactos y tratamientos acortados.” Mesa 3: Mejorando los tratamientos en TB, VIH y en COVID-19 y la adherencia a los mismos, Moderated by Maria Luiza de Souza and Andrés Marco). Rev Enf Emerg 2020;19(3):195-198 ([http://www.enfermedadesemergentes.com/articulos/a760/taller\\_TBC2020\\_mesa\\_3.pdf](http://www.enfermedadesemergentes.com/articulos/a760/taller_TBC2020_mesa_3.pdf))
20. **Castro K**. Parallels and mutual lessons between TB and COVID-19 (Spanish publication: “Paralelismo y lecciones mutuas entre TB y COVID-19.” Closing plenary keynote address, Moderated by Joan Caylá). Rev Enf Emerg 2021;20(3):233-235 (<http://enfermedadesemergentes.com/articulos/a804/clausura.pdf>)

21. Sahu S, Ditiu L, Bloom A, **Castro KG**, Ornstein T, Vincent C. The AIDP: Potential Impact for TB, Airborne Infectious Diseases, and Pandemic Preparedness. T20 Indonesia. AIDP Policy Brief. 2022  
([https://www.t20indonesia.org/wp-content/uploads/2022/10/TF6\\_The-AIDP\\_-\\_Potential-Impact-for-TB-Airbone-Infectious-Diseases-and-Pandemic-Preparedness.pdf](https://www.t20indonesia.org/wp-content/uploads/2022/10/TF6_The-AIDP_-_Potential-Impact-for-TB-Airbone-Infectious-Diseases-and-Pandemic-Preparedness.pdf))



### **Scientific Presentations and Invited Lectures**

1. AIDS: Epidemiologic Overview & Clinical Aspects. Annual Convention of the Alumni Association, University of Puerto Rico School of Medicine. San Juan, Puerto Rico. September 2, 1983.
2. AIDS: Epidemiologic Overview. National Convention of the American College of Emergency Physicians. Atlanta, Georgia. October 24, 1983.
3. Current Trends in AIDS. Epidemic Intelligence Service Seminar. Atlanta, Georgia. August 21, 1984.
4. AIDS in the United States: Epidemiologic Overview. Symposium on AIDS and Sexually Transmitted Diseases. Valencia, Spain. October 25, 1984.
5. AIDS: Trends of Cases Reported Outside High-Incidence Groups. 24<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapeutics. Washington, District of Columbia. October 9, 1984.
6. AIDS in Persons not in the High Incidence Groups. Epidemiology Exchange: Late Breaker Session. American Public Health Association Annual Meeting. Anaheim, California. November 14, 1984.
7. Epidemiology of AIDS. Southern Branch American Association for Laboratory Animal Science Annual Meeting. Atlanta, Georgia. March 20, 1985.
8. Risk Factors for AIDS Among Haitians in the United States. First International Conference on AIDS. Atlanta, Georgia. April 16, 1985.
9. Risk Factors for AIDS Among Haitians in the United States. 34<sup>th</sup> Epidemic Intelligence Service Conference. Atlanta, Georgia. April 23, 1985.
10. AIDS: Public Health Implications for Health-Care Workers. AIDS Update, D.C. General Hospital. Washington, D.C. September 11, 1985.
11. Epidemiology of AIDS in the United States: Perspectives for AIDS Prevention. Second Congress of the Chilean Infectious Disease Society. Santiago, Chile. October 11, 1985.
12. Meet the Professor Session - AIDS: Screening and Prevention. Second Congress of the Chilean Infectious Disease Society. Santiago, Chile. October 12, 1985.

13. Keynote Address: The AIDS challenge. AIDS Update, St. Joseph's Hospital. Atlanta, Georgia. November 6, 1985.
14. Epidemiology of AIDS in the Americas, and Sensitivity and Specificity of Laboratory Tests. AIDS Conference sponsored by the Pan American Health Organization. Guatemala City, Guatemala. December 2-3, 1986.
15. Epidemiology of AIDS in the United States. Pan American Health Organization Workshop to Develop Guidelines for AIDS and HTLV-III/LAV in Member Countries. Washington, District of Columbia. December 16, 1985.
16. The Epidemiology of AIDS in Belle Glade, Florida. 35<sup>th</sup> Epidemic Intelligence Service Annual Conference: Late-breaking Reports. Atlanta, Georgia. April 17, 1986.
17. Seroepidemiologic Studies of HTLV-III/LAV Infection in Belle Glade, Florida. II International Conference on AIDS. Paris, France. June 25, 1986.
18. AIDS: The Impact on the Hispanic Community. Sixth Biennial National Hispanic Conference on Health and Human Services. New York, New York. September 5, 1986.
19. The Acquired Immunodeficiency Syndrome: Epidemiology and Risk Factors for Transmission. Eighth Annual Research Forum, University of Puerto Rico Medical Sciences Campus. Rio Piedras, Puerto Rico. September 22, 1986.
20. AIDS and HTLV-III/LAV infection in Belle Glade, Florida. 26<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapeutics. New Orleans, Louisiana. September 29, 1986.
21. Epidemiology of AIDS in the World and the Americas. Fifth Clinical-Epidemiologic Update on Sexually Transmitted Diseases, Colombia Ministry of Health. Bogota, Colombia. October 31, 1986.
22. Moderator: Round-table discussion of norms for surveillance and prevention of sexually transmitted diseases and AIDS. Fifth Clinical-Epidemiologic Update on Sexually Transmitted Diseases, Colombia Ministry of Health. Bogota, Colombia. October 31, 1986.

23. AIDS Epidemiology and Surveillance in the United States. Second Pan American Health Organization Ad Hoc Meeting on AIDS. Washington, District of Columbia. December 8, 1986.
24. AIDS Epidemiology, Clinical Manifestations and Staging. AIDS Symposium, Third Pan American Congress of Infectious Diseases and Chemotherapy. San Juan, Puerto Rico. December 11, 1986.
25. AIDS Epidemiology from an International Perspective. U.S.- Mexico Border Epidemiologists & Veterinary Public Health Annual Meeting. Ciudad Juarez, Mexico. February 2, 1987.
26. AIDS Research and Epidemiology. AIDS Symposium, Pan American Health Organization, El Paso Field Office. Ciudad Juarez, Mexico. February 3, 1987.
27. HIV and AIDS: Epidemiologic Overview. Global Epidemic Intelligence Service Seminar. Mexico City, Mexico. March 2, 1987.
28. Update on AIDS Virus Transmission Patterns. Special Conference, National Blood Transfusion Center. Mexico City, Mexico. March 6, 1987.
29. Transmission of AIDS Virus in the United States: Special Focus on Minority Groups and Migrant Farmworkers. Tenth Annual Migrant Health Conference. South Padre Island, Texas. April 11, 1987.
30. Plenary Presentation: Acquired Immunodeficiency Syndrome. II Latin American and Fifth Colombian Congress on Tropical Medicine. Bogota, Colombia. May 27, 1987.
31. AIDS and HIV infection, Belle Glade, Florida. III International Conference on AIDS. Washington, District of Columbia. June 3, 1987.
32. Seroepidemiologic Studies of HIV in Belle Glade, Florida. Office of Technology Assessment Workshop: Can AIDS be transmitted by insects? Washington, District of Columbia. July 8, 1987.
33. Update on AIDS in the United States. First Pan American Teleconference on AIDS. Quito, Ecuador. September 14, 1987.
34. Moderator: Panel discussion on prevention and control of HIV infection and AIDS. First Pan American Teleconference on AIDS. Quito, Ecuador. September 15, 1987.

35. Panelist: Global, Regional, and National Strategies for AIDS Prevention and Control. First Pan American Teleconference on AIDS. Quito, Ecuador. September 15, 1987.
36. New Developments on the Epidemiology of AIDS. VI Latin American Congress on Sexually Transmitted Diseases. Guayaquil, Ecuador. September 16, 1987.
37. Update on the Revised Case Definition for AIDS Surveillance. AIDS Surveillance Workshop. San Juan, Puerto Rico. September 23, 1987.
38. Scientific Briefing on AIDS in Hispanic Populations. Hispanic Leadership Conference. San Antonio, Texas. October 28, 1987.
39. Epidemiology of HIV Infection in the United States. Annual Convention of the Puerto Rico Medical Association. San Juan, Puerto Rico. November 11, 1987.
40. HIV and AIDS surveillance at the Centers for Disease Control. AIDS Surveillance Seminar, Secretariat of Health, Dominican Republic. Santo Domingo, Dominican Republic. January 14, 1988.
41. Panelist: AIDS- Legal, Ethical, and Testing issues. Juvenile Corrections and Detention AIDS Conference, American Correctional Association. Atlanta, Georgia. February 14, 1988.
42. The Epidemiology of AIDS in the Hispanic Community. Latinos and AIDS: a National Strategy Symposium. Los Angeles, California. February 25, 1988.
43. Epidemiologic Trends of Sexually Transmitted Diseases in the United States. International Symposium in Dermatology. Seville, Spain. March 12, 1988.
44. Human Immunodeficiency Virus Infection in the United States: Epidemiology and Natural History. International Symposium in Dermatology. Seville, Spain. March 12, 1988.
45. AIDS: Ethics, Research, and Public Health. Inter-American University Colloquium. San German, Puerto Rico. March 29, 1988.
46. The Epidemiology of HIV and AIDS: Latinos and Others. XVI Annual Conference, National Association of Chicano Studies. Boulder, Colorado. April 15, 1988.
47. Natural History and Epidemiology of HIV Infection in the United States. Peruvian Infectious Diseases Society Meeting. Lima, Peru. May 26, 1988.

48. Frequency of Opportunistic Diseases in AIDS Patients, by Race/Ethnicity and HIV Transmission Categories--United States. IV International Conference on AIDS. Stockholm, Sweden. June 14, 1988.
49. HIV Transmission in Paid Plasma Donors in Mexico City. International AIDS Seminar, Centers for Disease Control. Atlanta, Georgia. July 13, 1988.
50. Epidemiology of HIV Infection and AIDS in Racial and Ethnic Minorities. National Conference on the Prevention of HIV Infection and AIDS Among Racial and Ethnic Minorities in the United States. Washington, District of Columbia. August 14, 1988.
51. Frequency of Opportunistic Diseases in AIDS Patients, by Race/Ethnicity and Transmission Categories-- United States. 28<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy. Los Angeles, California. October 25, 1988.
52. HIV/AIDS Update. National Conference on HIV Infection and AIDS Among Racial and Ethnic Populations. Washington, District of Columbia. August 13, 1989.
53. Panelist: Roundtable on Latinos and AIDS. American Public Health Association Annual Meeting. Chicago, Illinois. October 26, 1989.
54. Plenary Speaker: Spectrum of HIV-Related Illness, Therapeutic Advances, and Impact of AIDS in Hispanic Communities. Annual Meeting of the Puerto Rico Medical Association. San Juan, Puerto Rico. November 9, 1989.
55. Design and Conduct of HIV Seroepidemiologic Studies. Technical Workshop, Second Pan American Congress on AIDS. Santo Domingo, Dominican Republic. November 13, 1989.
56. Occupational Risk of HIV Infection in Health-Care Workers. AID Atlanta Meeting: HIV/SIDA in the Hispanic Community- An Update for Health Care Professionals. Atlanta, Georgia. March 8, 1990.
57. Epidemiology of HIV/AIDS and its Impact on Hispanic Populations. Symposium on Current Concepts in AIDS Research: Annual Meeting of Research Centers for Minority Institutions. San Juan, Puerto Rico. April 26, 1990.

58. AIDS: Why the Ethnic Imbalance? Hispanic Advisory Committee Seminar, National Institutes of Health. Bethesda, Maryland. May 23, 1990.
59. Association Between Mycobacterial Cultures and HIV Infection in a Large Municipal Hospital. VI International Conference on AIDS. San Francisco, California. June 21, 1990.
60. Epidemiology of HIV/AIDS in Correctional Facilities. Testimony: National Commission on AIDS. New York, New York. August 17, 1990.
61. Epidemiologic Assessment of AIDS in the Hispanic Community. Think Thank II, AIDS in Puerto Rico and the Puerto Rican Populations on the Mainland. San Juan, Puerto Rico. August 22, 1990.
62. Changing Patterns of Mycobacteria in a large municipal hospital, 1982 versus 1989. 30<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy. Atlanta, Georgia. October 24, 1990.
63. Risk of Occupational HIV Transmission in Health Care Workers. HIV Symposium, XIV Anniversary, Universidad del Caribe School of Medicine. Bayamon, Puerto Rico. November 9, 1990.
64. Epidemiology of HIV and AIDS in Puerto Rico and Other Parts of the United States. Testimony: National Commission on AIDS. San Juan, Puerto Rico. November 27, 1990.
65. HIV Update: Trends in HIV Infection Among Women, Adolescents, and Migrant Farmworkers. National Coalition of Advocates for Students Training. Atlanta, Georgia. February 12, 1991.
66. Epidemiological Comparison of HIV/AIDS in Puerto Rico and Other Areas of the United States. 7<sup>th</sup> Student Forum for Scientific Research, University of Puerto Rico Medical Sciences Campus. San Juan, Puerto Rico. March 9, 1991.
67. Transmission Routes of HIV. V Pan American Congress of Infectious Diseases. Lima, Peru. April 6, 1991.

68. Epidemiologic Investigation of HIV Transmission in a Dental Practice. V Pan American Congress of Infectious Diseases. Lima, Peru. April 6, 1991.
69. Recommendations for a National AIDS Program. V Pan American Congress of Infectious Diseases. Lima, Peru. April 7, 1991.
70. AIDS Among Hispanics Residing in the United States. V Pan American Congress of Infectious Diseases. Lima, Peru. April 9, 1991.
71. AIDS as a Sexually Transmitted Disease. National Council of La Raza Annual Conference. Houston, Texas. July 17, 1991.
72. HIV Transmission in Health-Care Settings. First Venezuelan Congress of Tropical Medicine and Infectious Diseases. Caracas, Venezuela. July 30, 1991.
73. Risk of Occupational HIV Transmission and Ways to Prevent It. The James F. Byrnes Medical Center Staff CME Committee's Summer Symposium on HIV and the Health-Care Worker. Columbus, South Carolina. August 1, 1991.
74. HIV/AIDS in Hispanic Communities in the United States. National Hispanic Conference on Substance Abuse Prevention, Treatment, and HIV/AIDS. Los Angeles, California. September 5, 1991.
75. Evidence of Human Immunodeficiency Virus Transmission in Correctional Facilities. 31st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, Illinois. September 30, 1991.
76. AIDS Epidemiology Update. Piedmont Hospital Department of Medicine, Friday Conference. Atlanta, Georgia. November 1, 1991.
77. HIV/AIDS and Other STDS in Racial/Ethnic Subpopulations, United States. American College of Epidemiology Annual Meeting. Atlanta, Georgia. November 8, 1991.
78. HIV Infection in Correctional Facilities. American Public Health Association Annual Meeting. Atlanta, Georgia. November 12, 1991.
79. Lessons for Epidemiologic Research from "No Identified Risk" Investigations. American Public Health Association Annual Meeting. Atlanta, Georgia. November 12, 1991.

80. New Classification System for HIV Infection in Adolescents and Adults. IV Biannual Symposium on Hepatitis and AIDS, "Octubre 12" Hospital. Madrid, Spain. November 28, 1991.
81. HIV Infection and Tuberculosis. American Medical Association Meeting on Infection Control Measures/Policies to Prevent Nosocomial Transmission of Tuberculosis. Chicago, Illinois. July 1, 1992.
82. Revised Classification System for HIV Infection in Adolescents and Adults. VIII International Conference on AIDS/III STD World Congress. Amsterdam, The Netherlands. July 19-24, 1992.
83. The Reappearance of Tuberculosis within the AIDS Epidemic. X Anniversary of the Pan American Society of Infectious Diseases, Infectious Diseases Society of America Annual Meeting. Anaheim, California. October 10, 1992.
84. HIV Infection: An Update. Rheumatology 1992- Sponsored by Emory University School of Medicine, Department of Medicine, Division of Rheumatology. Atlanta, Georgia. October 17, 1992.
85. Moderator: The Epidemiology of HIV/AIDS in the Puerto Rican Community; and Panelist: Public Policy Affecting Puerto Ricans with HIV/AIDS. Conference on the HIV/AIDS Epidemic in a Commuting Population. Lehman College of the City University of New York. Bronx, New York. November 12, 1992.
86. TB and HIV: challenge to clinicians in the 90's. Symposium on Transmission of Infectious Diseases in the Health-Care Setting. Southern Medical Association Annual Convention. San Antonio, Texas. November 13, 1992.
87. Tuberculosis and HIV. International Symposium on Advances in Medicine. University of Las Palmas, Gran Canaria, Spain. February 26, 1993.
88. Moderator: HIV/AIDS Symposium. International Symposium on Advances in Medicine. University of Las Palmas, Gran Canaria, Spain. February 26-27, 1993.
89. Tuberculosis- an Increasing Public Health Problem. The Hubert H. Humphrey Fellowship Workshop. Atlanta, Georgia. March 22, 1993.



90. Panel Discussant: A Workshop for Judges on HIV/AIDS and Tuberculosis. American Society for Law, Medicine, and Ethics. Miami, Florida. April 15, 1993.
91. Multidrug-Resistant Tuberculosis. In: Tuberculosis: the Current Crisis. Tenth Annual National Preventive Medicine Meeting. St. Louis, Missouri. April 18, 1993.
92. Moderator: Tuberculosis-- the Epidemic Continues. 42<sup>nd</sup> Epidemic Intelligence Service Annual Conference. Atlanta, Georgia. April 20, 1993.
93. Tuberculosis Update. National Oral Health Conference. Atlanta, Georgia. April 27, 1993.
94. AIDS Overview. VI Pan American Congress of Infectious Diseases and X Chilean Congress of Infectious Diseases. Viña del Mar, Chile. May 26, 1993.
95. Impact of Multidrug-Resistant Tuberculosis in the United States. VI Pan American Congress of Infectious Diseases and X Chilean Congress of Infectious Diseases. Viña del Mar, Chile. May 26, 1993.
96. HIV and Tuberculosis-- Epidemiology, Testing, and Infection Control. American Medical Association International Conference on HIV Early Intervention. Berlin, Germany. June 5, 1993.
97. Workshop Participant: International Surveillance of Tuberculosis Drug Susceptibility. International Union Against Tuberculosis and Lung Diseases. Paris, France. October 6, 1993.
98. Moderator: Tuberculosis in the 1990's - Sound the Alarm. 33<sup>rd</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, Louisiana. October 19, 1993.
99. Panelist: Tuberculosis Update. Employee Health in the 1990s: Protecting and Serving Health Care Workers. Beth Israel Medical Center. New York, New York. January 25, 1994.
100. Epidemiology and Emergence of Drug Resistant Tuberculosis. American Federation for Clinical Research, Southern Society for Clinical Investigation Meeting. New Orleans, Louisiana. February 5, 1994.
101. Tuberculosis: a new occupational health problem? 1<sup>st</sup> National Congress of Spanish Occupational Health Specialists. Madrid, Spain. March 9, 1994.

102. Tuberculosis: reemergence of an old disease. Minnesota Department of Health's Vaccine-Preventable Diseases and Tuberculosis Conference. Minneapolis, Minnesota. April 6, 1994.
103. Tuberculosis in the United States. U.S.-Mexico Border Tuberculosis Review Meeting. El Paso, Texas. April 14, 1994.
104. The Resurgence of Tuberculosis in the 1990's. Department of Medicine Grand Rounds. University of Texas Health Sciences Center, San Antonio, Texas. May 4, 1994.
105. Keynote Address: The Role of the Tuberculosis Nurse in Tuberculosis Control. American Thoracic Society TB Nurses Special Interest Group. 1994 International Conference of the American Lung Association and American Thoracic Society. Boston, Massachusetts. May 21, 1994.
106. Tuberculosis: A National Perspective. 1994 Florida HIV/STD/TB Conference. Ft. Lauderdale, Florida. June 2, 1994.
107. Tuberculosis and HIV in Industrialized Countries. Global Congress on World Health/28<sup>th</sup> World Conference of the International Union Against Tuberculosis and Lung Disease. Mainz, Germany. June 16, 1994.
108. Progress Toward TB Elimination. 44<sup>th</sup> Annual Tuberculosis/Respiratory Disease Institute Blue Ridge Assembly. Black Mountain, North Carolina. July 22, 1994.
109. The Current Epidemiology of Tuberculosis. Tuberculosis and Behavior: National CDC/NIDA/NIH Workshop on Research for the 21<sup>st</sup> Century. Bethesda, Maryland. August 29, 1994.
110. Plenary Presentation: Tuberculosis in the 1990's. XIII<sup>th</sup> Colombian Internal Medicine Conference. Medellin, Colombia. September 25, 1994.
111. Plenary: Epidemiology of *Mycobacterium tuberculosis* Drug Resistance in the United States, 1975-1993. Joint ICAAC/IDSA Symposium on the Epidemiology of Emerging Antimicrobial Resistance. 34<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy. Orlando, Florida. October 7, 1994.
112. BCG Vaccine: Current Recommendations. III<sup>rd</sup> International Immunization Workshop, "Octubre 12" Hospital. Madrid, Spain. December 1, 1994.

113. Tuberculosis, a Reemerging Infectious Disease. IV<sup>th</sup> International Conference on Travel Medicine. Acapulco, Mexico. April 25, 1995.
114. Featured Speaker: The Epidemiology of Tuberculosis in the 1990's. American Thoracic Society/American Lung Association International Conference. Seattle, Washington. May 24, 1995.
115. Multidrug Resistant Tuberculosis. VII<sup>th</sup> Pan American Infectious Diseases Conference. Cartagena, Columbia. May 29, 1995
116. Tuberculosis and AIDS. VII<sup>th</sup> Pan American Infectious Disease Conference. Cartagena, Colombia. May 30, 1995.
117. Tuberculosis in Children. "V Jornadas Internacionales de Avances en Pediatría, Hospital Materno Infantil." University of Las Palmas, Gran Canaria. Gran Canaria, Spain. May 24, 1996.
118. Current Issues in Tuberculosis Control. National Conference of State Legislatures Meeting. Atlanta, Georgia. June 6, 1996.
119. Public Health Perspectives and Priorities on Vaccine Development and Application. Comstock Conference on Epidemiology and Control of Tuberculosis: Vaccines and Tuberculosis Control. Baltimore, Maryland. June 12, 1996.
120. Keynote Address: TB Prevention in the 90's. American Lung Association of Eastern Missouri. St. Louis, Missouri. November 14, 1996.
121. Tuberculosis Vaccines. "V Jornadas Internacionales Sobre Actualización en Vacunas, Hospital 12 de Octubre." Madrid, Spain. February 13, 1997.
122. Recommendations for Rifampicin and Protease Inhibitor Treatment of Tuberculosis and HIV. 2nd International Symposium on Mycobacteria of Clinical Interest. Cordoba, Spain. June 20, 1997.
123. Tuberculosis and Non-tuberculous Mycobacteria in Women. Annual Meeting of the Infectious Disease Society of Obstetrics and Gynecology. Fajardo, Puerto Rico. August 6, 1997.
124. Advances in the Management of Multidrug-resistant Tuberculosis. Consensus Workshop on the Prevention and Control of Tuberculosis in Mexico. Instituto Nacional de la Nutricion, Mexico City, Mexico. September 24, 1997.

125. Tuberculosis Vaccines. Vaccines 1998: II Update Course. Hospital Vall D'Hebron, Barcelona, Spain. April 30, 1998.
126. Magnitude of Tuberculosis in Developed Countries and the Role of Vaccines. 1998 International Symposium on Tuberculosis Vaccine Development and Evaluation. San Francisco, California. August 26, 1998.
127. Opportunistic Infections in the Americas: problems with diagnosis and management in developing and developed countries. Meet-the-Expert Session. 38<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, California. September 25, 1998.
128. Tuberculosis Update. Slide Session 169-L. Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, California. September 27, 1998.
129. Tuberculosis in the HIV-infected. 36<sup>th</sup> Annual Meeting of the Infectious Diseases Society of America. Denver, Colorado. November 12, 1998.
130. DOTS more easily in the United States: how far can we go? 29<sup>th</sup> World Conference of the International Union Against Tuberculosis and Lung Diseases. Bangkok, Thailand. November 24, 1998.
131. Dr. Arturo L. Carrión Award Keynote Lecture: Multidrug Resistant Tuberculosis in the United States: recent experience and advances. Semi-Annual Convention, The Puerto Rico Society of Microbiologists, American Society of Microbiology Branch. Rio Piedras, Puerto Rico. January 23, 1999.
132. Lessons from TB for HIV. 4<sup>th</sup> Annual Meeting, International Union Against TB and Lung Diseases, North American Region. Chicago, Illinois. February 27, 1999.
133. Will Collaborations Lead to Better Outcomes? STOP TB Initiative Session, 30<sup>th</sup> International Union Against Tuberculosis and Lung Disease World Conference on Lung Health. Madrid, Spain. September 15, 1999.
134. The Role of Government in Tuberculosis Prevention and Control. 127<sup>th</sup> Annual Meeting, American Public Health Association. Chicago, Illinois. November 9, 1999.

135. Moderator: Tuberculosis and Hepatitis: current challenges in public health. 127<sup>th</sup> Annual Meeting, American Public Health Association. Chicago, Illinois. November 10, 1999.
136. Convener: The Molecular Basis of *Mycobacterium tuberculosis* Pathogenesis and Transmission. 37<sup>th</sup> Annual Meeting, Infectious Diseases Society of America. Philadelphia, Pennsylvania. November 18, 1999.
137. Closing Remarks: Workshop on Tuberculosis Control in the 21<sup>st</sup> century. American Thoracic Society and American College of Chest Physicians. Crystal City, Virginia. December 12, 1999.
138. Future Challenges. U.S. and Mexico: Together Against TB in the 21<sup>st</sup> Century. Global Health Council. San Diego, California. March 3, 2000.
139. Implications of Tuberculin Skin Test Conversions in Healthcare Personnel. 4<sup>th</sup> Decennial International Conference on Nosocomial and Healthcare-Associated Infections. Atlanta, Georgia. March 7, 2000.
140. Plenary Speaker: Tuberculosis Control: challenges and opportunities in an unequal world. XXV<sup>th</sup> Annual Meeting, Asociación Mexicana de Infectología y Microbiología Clínica. León, Guanajuato, Mexico. June 30, 2000.
141. Challenges for TB Elimination and Updated Recommendations for Targeted Tuberculin Testing and Treatment of Latent Infection. 50<sup>th</sup> Anniversary A. G. Holley State Hospital and Grand Rounds. Lantana, Florida. July 19, 2000.
142. Premiere Herman F. Easom, M.D. Golden Anniversary Lecture: Milestones of Tuberculosis Control in the United States. 50<sup>th</sup> Annual Tuberculosis-Respiratory Disease Institute, Blue Ridge Assembly. Black Mountain, North Carolina. July 22, 2000.
143. Tuberculin Skin Testing and Treatment of Latent Infection. XXIV Inter American Medical Dental Congress, Spanish American Medical Dental Society of New York. New York, NY. October 7, 2000.
144. Tuberculosis and Migration. X<sup>th</sup> Congress of the Pan American Infectious Diseases Society. Guadalajara, Mexico. May 4, 2001.

145. Tuberculosis Update and Challenges for its Elimination in the United States. Scientific Meeting of the Basque Country Tuberculosis Prevention and Control Program. Vitoria, Spain. May 10, 2001.
146. Global Tuberculosis Update. (And Roundtable Moderator). XXVIIIth Peruvian American Medical Society Annual Convention. Trujillo, Peru. July 5, 2001.
147. Tuberculosis and HIV: Mutual Lessons for Improved Health. (And Session Co-moderator). 1<sup>st</sup> International AIDS Society Conference on HIV Pathogenesis and Treatment. Buenos Aires, Argentina. July 7, 2001.
148. Tuberculosis Control & Prevention Policies. Puerto Rico Lung Association 70<sup>th</sup> Anniversary. San Juan, Puerto Rico. October 19, 2001.
149. Tuberculosis Elimination in the United States: is it possible and what will it take? Tuberculosis Workshop, 39<sup>th</sup> Annual Meeting of the Infectious Diseases Society of America. San Francisco, California. October 25, 2001.
150. AIDS and Tuberculosis in the United States. Vth International Workshop on Tuberculosis. Barcelona, Spain. November 6, 2001.
151. CDC Contribution to Tuberculosis Control in the Baltics and Russia. 12<sup>th</sup> Interagency Coordinating Committee focusing on tuberculosis, World Health Organization European Region. Copenhagen, Denmark. January 22, 2002.
152. Beyond DOTS: new strategies and methodologies. 7<sup>th</sup> Annual Conference, North American Region, International Union Against Tuberculosis and Lung Diseases. Vancouver, Canada. March 2, 2002.
153. Tuberculosis Update. Medical Grand Rounds, University of Medicine and Dentistry of New Jersey. Newark, New Jersey. March 22, 2002
154. Perspectives and Prospects for the Elimination of Tuberculosis in the U.S. International Public Health Convention 2002 and V National Congress on Hygiene and Epidemiology. Havana, Cuba. May 3, 2002.
155. Tuberculosis Update. American Thoracic Society 98th International Conference. Atlanta, Georgia. May 19, 2002.

156. The TB Epidemic in the U.S., 1992-2000. 4<sup>th</sup> World Congress on Tuberculosis. Washington, District of Columbia. June 3, 2002.
157. Public Health Policies in TB Prevention and Control. Fifth Seminar: Education in Tuberculosis 2002. San Juan, Puerto Rico. June 8, 2002.
158. CDC Contribution to TB Control in Russia and Central Asian Republics. Congressional Task Force on International HIV/AIDS Briefing. Washington, District of Columbia. June 13, 2002.
159. Monitoring TB and HIV. XIV International AIDS Conference. Barcelona, Spain. July 9, 2002.
160. Tuberculosis Update. 10<sup>th</sup> U.S.-Russia Health Committee Meeting. Washington, District of Columbia. July 31, 2002.
161. Invited Presentation: Tuberculosis Control Challenges When Providing Technical Support. TB Interagency Coordinating Committee. Moscow, Russia. September 24, 2002.
162. Tuberculosis Briefing. Meeting of the Advisory Council for the Elimination of Tuberculosis with Assistant Secretary, U.S. Department of Health and Human Services (Dr. Eve Slater). Washington, District of Columbia. September 26, 2002.
163. Overview: Tuberculosis and Human Immunodeficiency Virus (HIV) Coinfection. Pre- IUATLD Conference TB/HIV Workshop Sponsored by Treatment Action Group. Montreal, Canada. October 5, 2002.
164. Congressional Briefing with Representative Sherrod Brown on the Impact of Global TB in the U.S. February 12, 2003.
165. TB Research Scientific Advisory Board, Harvard University's Partners in Health, Gates Foundation-sponsored research review. Boston, MA. March 4, 2003.
166. Invited Presentation: Role Models for Hispanics in the U.S. Department of Health and Human Services. 7<sup>th</sup> Annual Conference, National Hispanic Medical Association. Washington, District of Columbia. March 21, 2003.

167. Invited Remarks, U.S. Agency for International Development World TB Day Press Conference. National Press Club, Washington, District of Columbia. March 24, 2003.
168. The Binational U.S.-Mexico Tuberculosis Referral and Case Management Project. World TB Day Observance. El Paso, Texas. March 27, 2003.
169. Co-Chair: Treatment of TB: new data from clinical trials and demonstration projects. 99<sup>th</sup> International Conference of the American Thoracic Society. Seattle, Washington. May 18, 2003.
170. Invited Keynote Speaker: Global impact of TB on the Epidemiology, Diagnosis, and Treatment in the U.S. 11<sup>th</sup> Primary Care Congress, Puerto Rico Academy of Geriatrics. San Juan, Puerto Rico. June 22, 2003.
171. Invited Presentation T1-G0601: Integration of HIV Prevention and Care with TB Treatment. 2003 HIV Prevention Conference. Atlanta, Georgia. July 29, 2003.
172. Strategies for Global TB Elimination. Thailand-Hawaii Rounds. Tripler Army Medical Center. Honolulu, Hawaii. August 5, 2003.
173. TB Treatment Guidelines. Hawaii Thoracic Society. Honolulu, Hawaii. August 7, 2003.
174. Healthy People 2010 Focus Area Progress Review (Immunization and Infectious Diseases) for Acting Assistant Secretary, U.S. Department of Health and Human Services (Dr. Cristina Beato). Washington, District of Columbia. August 20, 2003.
175. Invited Presentation: Tuberculosis Elimination: a Tool for Reducing Health Disparities. Tennessee Public Health Association Conference on Emerging Infectious Diseases. Franklin, Tennessee. September 18, 2003.
176. Invited Presentation: Studies for the Treatment of Latent Tuberculosis Infection in the United States. VI International Workshop on Tuberculosis. Barcelona, Spain. October 28, 2003.
177. Guest presenter, plenary session *Focus on the Present*. Division of Tuberculosis Elimination Plaque recognition to the American Lung Association on its Centennial Celebration. American Thoracic Society and American Lung Association 100<sup>th</sup> International Conference. Orlando, Florida. May 23, 2004.



178. Invited Presentation: Tuberculosis and Immigration, the U.S. Experience. XXXVII National Congress of the Spanish Pulmonary Society (SEPAR). Madrid, Spain. June 5, 2004.
179. Invited Presentation: Guidelines and Strategies for Improving Adherence to Treatment for Latent TB Infection. III Central American and Caribbean and VII National Infectious Diseases Congress. Santo Domingo, Dominican Republic. August 26, 2004.
180. Invited Presentation: Tuberculosis and HIV. III Central American and Caribbean and VII National Infectious Diseases Congress. Santo Domingo, Dominican Republic. August 27, 2004.
181. Invited Presentation: TB and HIV Infections: problems and management. XVIII Inter American Medical Dental Congress. New York, New York. October 9, 2004.
182. Invited Presentation: Update on TB in the World and Latin America. XVIII Inter American Medical Dental Congress. New York, New York. October 9, 2004.
183. Keynote Address: Future Challenges in TB Elimination. Northeast TB Controllers Conference. Newport, Rhode Island. October 19, 2004.
184. Invited Presentation: Sustaining Achievements in TB Control Symposium. 35<sup>th</sup> UNION World Conference on Lung Health. Paris, France. November 1, 2004.
185. Invited Presentation: Global Tuberculosis: Realities and Challenges. BOTUSA 10<sup>th</sup> Anniversary. Gaborone, Botswana. March 1, 2005.
186. Jayne Ash Memorial Keynote Address: New Tools for TB Control in the 21<sup>st</sup> Century. California TB Controllers Annual Conference. Emeryville, California. May 12, 2005.
187. Invited Presentation: Infection Control Precautions for TB in Low Income countries. XIIth Congress of the Pan American Infectious Diseases Society. Caracas, Venezuela. May 16, 2005
188. Invited Presentation: Drug-Drug Interactions in the Management of TB and HIV. XIIth Congress of the Pan American Infectious Diseases Society. Caracas, Venezuela. May 17, 2005.

189. Invited Presentation: Clinical Manifestations of TB in HIV-infected Patients. 1st Scientific Congress of "Ciudad Sanitaria Dr. Luis E. Aybar." Santo Domingo, Dominican Republic. June 23, 2005.
190. Roundtable Discussant: Management of ARVs in patients with TB. 1st Scientific Congress of "Ciudad Sanitaria Dr. Luis E. Aybar." Santo Domingo, Dominican Republic. June 25, 2005.
191. Invited Presentation: Recent Tuberculosis Trends in Racial/Ethnic Minorities, United States. 43<sup>rd</sup> Annual Meeting of the Infectious Diseases Society of America: ID challenges in Minority Populations Symposium. San Francisco, California. October 9, 2005.
192. Invited Presentation: Adherence to ARVs: What Does and Doesn't Work? (Scaling Up TB-HIV Care Symposium). 36<sup>th</sup> International Union Against Tuberculosis and Lung Disease World Conference on Lung Health. Paris, France. October 22, 2005.
193. Invited Presentation: Update on New tools to Diagnose Tuberculosis. 64<sup>th</sup> Annual Meeting of the United States-Mexico Border Health Association. Monterrey, Mexico. May 2, 2006.
194. Invited Presentation: Extensively Drug Resistant Tuberculosis. 37<sup>th</sup> International Union Against Tuberculosis and Lung Disease World Conference on Lung Health. Paris, France. October 30, 2006.
195. Co-moderator. Special Session on XDR TB: how did we get here are what are we doing about it? 37<sup>th</sup> International Union Against Tuberculosis and Lung Disease World Conference on Lung Health. Paris, France. November 2, 2006
196. Emergence of Extensively Drug Resistant Tuberculosis: Failure of TB Control Strategy? Pan American Health Organization Seminar and Workshop on Sustainable Regional Response to MDR and XDR TB. Santo Domingo, Dominican Republic. March 29, 2007
197. New Guideline Overview: Controlling Tuberculosis in the United States. Georgia Statewide TB Training. Peachtree City, Georgia. April 11, 2007
198. Extensively Drug Resistant Tuberculosis. (Video-teleconference presentation from CDC Atlanta) Session D7. Drug Resistant TB: Global Implications of a Man Made Threat. 34<sup>th</sup> International Conference on Global Health. Washington, District of Columbia. June 1, 2007.

199. Keynote Address: The Elimination of Tuberculosis in the United States (videotaped presentation from CDC Atlanta). 82<sup>nd</sup> Japanese Respiratory Society Conference. Osaka, Japan. June 5, 2007.
200. Santiago Ramón y Cajal Memorial Lecture: Drug Resistance in Tuberculosis: challenges and the way forward. Spanish American Medical and Dental Society of New York. New York, New York. October 27, 2007.
201. The Challenge of Drug Resistant Tuberculosis. 2<sup>nd</sup> Southeastern Mycobacteria Meeting, University of Georgia. Athens, Georgia. January 19, 2008.
202. Plenary Presentation: How Can We Use New Tools to Strengthen Our Commitment to Global TB Control? 12<sup>th</sup> Annual Conference IUATLD North America Region. San Diego, California. February 29, 2008.
203. Plenary Presentation: Lessons from MDR TB in the United States: Application to Global XDR TB Response. 2008 International Conference on Emerging Infectious Diseases. Atlanta, Georgia. March 17, 2008.
204. Infectious Diseases Seminar: Extensively Drug Resistant Tuberculosis. Emory University School of Medicine. Atlanta, Georgia. April 24, 2008.
205. Report on 2<sup>nd</sup> WHO Task Force on XDR TB. Stop TB Partnership Coordinating Board Meeting. Cairo, Egypt. May 7, 2008.
206. FDA, Center for Drug Evaluation and Research Invited Seminar: Extensively Drug Resistant Tuberculosis. Rockville, Maryland. May 28, 2008.
207. Plenary Presentation: Tuberculosis — The Big Picture 2008. Association of Public Health Laboratories, 5<sup>th</sup> National Conference on Laboratory Aspects of Tuberculosis. San Diego, California. August 11, 2008.
208. Invited Presentation: Extensively Drug Resistant TB: Lessons from USA. 63<sup>rd</sup> National Conference on Tuberculosis and Chest Diseases, and First International Union Against Tuberculosis and Lung Diseases Conference of Southeast Asia Region. Delhi, India. September 8, 2008.

209. Invited Lecturer: Tuberculosis. Post-graduate MSc Course “Challenges in Global Health,” University of Oxford, Department of Public Health. Oxford, United Kingdom. October 13, 2008.
210. Department of Medicine Grand Rounds: Global Challenges to the Elimination of TB in the U.S. *2<sup>nd</sup> Annual Dr. Reynard McDonald World TB Day Lecture*. University of Medicine and Dentistry of New Jersey. Newark, New Jersey. March 17, 2009.
211. Invited Speaker: Novel Swine-Origin Influenza A (H1N1) In Humans, United States, 2009. 2009 American Thoracic Society International Conference. Late- Breaking Session on Influenza A (H1N1). San Diego, California. May 19, 2009.
212. Multi-Drug Resistant Tuberculosis, Occurrence in the U.S. and Globe: Treatment, Outcomes. Anti-Infective Drugs Advisory Committee, Food and Drug Administration. Silver Spring, Maryland. June 3, 2009.
213. Medical Grand Rounds: Global Challenges to the Elimination of TB in the U.S. A.G. Holley Hospital. Lantana, Florida. July 8, 2009.
214. Tuberculosis in the U.S. and Globe: Treatment, Drug-resistance, Outcomes. Public Workshop on the Design and Clinical Trials of Antimycobacterial Drugs. Food and Drug Administration. Silver Spring, Maryland July 30, 2009.
215. Impact of HIV in the Prevention and Control of Multi- and Extensively-drug Resistant TB (Spanish). VIII Regional Stop TB Interagency Meeting. Rio de Janeiro, Brazil. September 1, 2009.
216. Plenary Presentation: Global Response to the Threat of Extensively Drug Resistant TB. 1<sup>st</sup> Kenya National Lung Health Scientific Conference. Kenyatta International Conference Center, Nairobi, Kenya. October 9, 2010.
217. Medical Service Grand Rounds: Novel 2009 Influenza A (H1N1) in the U.S. (Spanish). Veterans Administration Hospital. Rio Piedras, Puerto Rico. November 24, 2009.
218. Keynote Address: 2009 Influenza A (H1N1) Response: Role of USPHS Commissioned Corps. Anchor and Caduceus Dinner, Commissioned Officers Association Atlanta Branch. Fort McPhearson, Atlanta, Georgia. January 23, 2010.
219. Invited Keynote Lecture: Present and Future of Diagnostic Laboratory for Tuberculosis (Spanish). VII Educational Congress for Medical Technologists. Puerto Rico College of Medical Technologists. Isla Verde, Puerto Rico. March 18, 2010.

220. Invited Speaker: Tuberculosis Guidelines Development and Dissemination in the USA. IV National TB Meeting/ I Brazilian Stop TB Partnership Forum. Rio de Janeiro, Brazil. May 27, 2010.
221. Invited Presentation: Tuberculin Skin Test: Obstacle or Solution? How Can the Botswana Isoniazid Preventive Therapy Trial Results Impact IPT Scale-Up? IV National TB Meeting/ I Brazilian Stop TB Partnership Forum. Rio de Janeiro, Brazil. May 28, 2010.
222. Invited Presentation: Domestic Challenges in Tuberculosis Elimination. 2010 International Conference on Emerging Infectious Diseases. Atlanta, Georgia. July 13, 2010.
223. Invited Speaker: Global Emergence of Extensively Drug resistant tuberculosis. Thaler Lecture Series, AERAS Global TB Vaccine Foundation. Rockville, Maryland. July 20, 2010.
224. Invited Speaker: Barriers to Tuberculosis Elimination in the United States: Role of Health Disparities, Poverty, and Social Determinants. APHA 136<sup>th</sup> Annual Meeting & Expo Session 3011.0. Denver, Colorado. November 8, 2010.
225. Invited lecture: Global Response to the Challenge of Tuberculosis. Emory University School of Medicine Infectious Diseases Research Seminar. Atlanta, Georgia. February 3, 2011.
226. Invited presentation: Role of Treatment of Latent TB Infection in United States. PAHO V<sup>th</sup> Meeting of Low TB Prevalence Countries in the Americas. Isla Verde, Puerto Rico. March 3, 2011.
227. Congressional briefing: Tuberculosis in the United States: Briefing for the United States House of Representatives convened by Congressman Eliot Engel (D-NY-17) and organized with American Thoracic Society and Global Stop TB Partnership. Washington, District of Columbia. March 29, 2011.
228. Invited Lecture: New Methods for the Diagnosis of Tuberculosis (Spanish). Infectious Disease Society of Puerto Rico Annual Meeting. Fajardo, Puerto Rico April 2, 2011.
229. Invited Lecture: Non-tuberculosis Mycobacteria Update. Infectious Disease Society of Puerto Rico Annual Meeting. Fajardo, Puerto Rico April 3, 2011.

230. Invited Lecture: Present and Future Treatment of Multi- and Extensively-Drug Resistant TB. XV Congress of the Spanish Society for Infectious Diseases and Clinical Microbiology (SEIMC). Malaga, Spain. June 3, 2011.
231. Invited Discussant: Revising Case Definitions for MDR and XDR TB. WHO TB Strategic and Technical Advisory Group. Geneva, Switzerland. June 20, 2011.
232. Invited Lecture: HIV and TB Co-infection. 14<sup>th</sup> Annual Conference Ryan White AIDS Program. Tampa, Florida. 27 June 2011.
233. Invited Presentation: Public Health Implications of FDA Reclassification of Medical Diagnostics for TB. Meeting of the Microbiology Devices Panel, FDA Medical Devices Advisory Committee. Rockville, Maryland. June 29, 2011.
234. Invited Presentation: Challenges to TB Prevention, Control, and Elimination in Countries with Low and Intermediate Burden: Lessons from the USA. New Plan for TB Elimination 2020 in Korea. Korea Center for Disease Control & Prevention. O-song, Korea. August 25, 2011.
235. Invited Research Lecture: TB Genotyping: from Research to Practice. University of Arkansas for Medical Sciences (UAMS). Little Rock, Arkansas. September 28, 2011.
236. Twelfth Annual Joseph H. Bates M.D. Visiting Professor Lecture. Challenges to the Elimination of Tuberculosis in the United States. UAMS Medical Grand Rounds. Little Rock, Arkansas. September 29, 2011.
237. Co-Moderator, Symposium 35. Update on Diagnostics and Treatment of Complex, Multidrug Resistant TB. Infectious Diseases Society of America 49<sup>th</sup> Annual Meeting. Boston, Massachusetts. October 20, 2011.
238. Invited Presentation, Symposium 11. Controversies in HIV: “Should we fully integrate TB and HIV programmes into one unified programme: from WHO headquarters Geneva to the district hospital in Africa?” 42<sup>nd</sup> Union World Conference on Lung Health. Lille, France. October 28, 2011.
239. Invited Presentations. XV International Workshop on Tuberculosis, Tuberculosis Investigation Unit of Barcelona. “TB Outbreaks and Molecular

Epidemiology: Experience and Prospects in the U.S.” and “TB Epidemiology in U.S. and Urban Areas.” Barcelona, Spain. November 28-29, 2012.

240. World TB Day Congressional Briefing. “Tuberculosis—Why this Ancient Disease Remains a Global (and Domestic) Health Threat.” House of U.S. Congress, Rayburn Building, Washington, District of Columbia. March 20, 2012.
241. Invited Lecture, Global Issues in Antimicrobial Resistance. “Drug Resistance in Tuberculosis: Basis, Occurrence, and Prevention.” Emory University Rollins School of Public Health. Atlanta, Georgia. April 6, 2012.
242. Lecture, CDC Advanced Mycobacteriology Course. “Tuberculosis Elimination in the United States and Globe.” Atlanta, Georgia. April 24, 2012.
243. Invited Presentation: Aspiring to Zero Tuberculosis Deaths, Harvard University. “Reaching Zero Tuberculosis in the United States: Lessons Learned.” Cambridge, Massachusetts. May 31, 2012.
244. Invited Presentation. 1<sup>st</sup> Zero TB America Conference, Korean Community Presbyterian Church. “Zero Tuberculosis in the United States: Lessons Learned.” Duluth, Georgia. Sept 8, 2012.
245. Invited Presentation. Treatment Action Group Satellite Symposium: Reaching Zero Deaths and Zero New Infections. “Setting the Stage for TB Elimination: Lessons from Smallpox Eradication.” 43<sup>rd</sup> Union World Conference on Lung Health. Kuala Lumpur, Malaysia. November 13, 2012.
246. Invited Presentation. FDA Anti-Infective Drugs Advisory Committee. “U.S. and Global Tuberculosis Perspective on Drug Resistance and Prospects for Elimination.” FDA. Silver Spring, Maryland. November 28, 2012.
247. Invited Lecture: “TB Elimination in the United States.” TB Program Manager’s Course. CDC, Atlanta, Georgia. January 28, 2013.
248. Invited Commentary. Global Stop TB Partnership, Post-2015 TB Targets Workshop: “Global Smallpox Eradication: Applicable Lessons to Tuberculosis Elimination in the U.S. and Globe.” World Health Organization, Geneva, Switzerland. February 7, 2013.
249. Invited to provide U.S. Congress TB Caucus Briefing. “Tuberculosis in the United States.” Washington, District of Columbia. March 20, 2013.
250. Invited Presentation. Yale AIDS Colloquium Series, center for Interdisciplinary Research on AIDS. “Challenges to the Elimination of

Tuberculosis in the United States.” Yale University School of Public Health and School of Medicine. New Haven, Connecticut. March 28, 2013.

251. Three Invited Presentations (Spanish). “What Treatment Regimens for Latent TB Infection Should We Use and for Whom?”; “TB Elimination in the U.S.: Opportunities and Challenges”; “Political Will: A Crucial Component of TB Elimination.” PAHO VI Regional Meeting of Low TB Prevalence Countries in the Americas. Santiago, Chile. April 17-18, 2013.
252. Invited Presentation: “Strategic Vision for the Future.” National Tuberculosis Conference, Atlanta, Georgia. June 11, 2013.
253. Healthy People 2020 Progress Review. “TB Elimination in the United States.” U.S. Department of Health and Human Services. Washington, District of Columbia. July 30, 2013.
254. Invited Lecture: “Learning from the HIV Experience: Continuum of Care Initiative.” Treatment Action Group Satellite Symposium: Cascades for Patient Retention and Cure. 44<sup>th</sup> Union World Conference on Lung Health. Paris, France. November 1, 2013.
255. Invited Lecture: “Global Tuberculosis: a Re-emerging Infectious Disease.” Emory University Rollins School of Public Health. Atlanta, Georgia. February 7, 2014.
256. HIV Keynote Presentation: “HIV and TB – the Intersection of Two Epidemics.” 2014 HIV/STD Update: Advances in Care and Prevention. Indiana University-Purdue University Center for HIV Research. Indianapolis, Indiana. May 9, 2014.
257. Invited Speaker: “CDC and HRSA HIV Prevention and Care Integrated Planning.” Regional Resource Network Program, U.S. Department of Health and Human Services, Region IV and VI. Integration of HIV Care and Prevention Planning: a Southern View. Atlanta, Georgia. August 12, 2014.
258. Invited Keynote Address. Critical Path to Tuberculosis Drug Regimens (CPTR) 2014 Workshop. Washington, District of Columbia. September 24, 2014.
259. Invited Presentation: “Contact Investigations as an Important Tool to Prevent and Control TB and HIV.” XVIII International Workshop of the Barcelona Unit for Tuberculosis Research (UITB) and 45<sup>th</sup> Union World Conference on Lung Health. Barcelona, Spain. October 28, 2014.



260. Invited Keynote address and receipt of Honorary Public Health Advisor Award. The Watsonian Society Banquet. Atlanta, Georgia. October 22, 2016.
261. Invited Presentation: "TB Elimination: Aiming for Success." Workshop 5: Thinking Out of the Box: Different Approaches to TB Elimination in the U.S. American Thoracic Society 2015 International Conference. Denver, Colorado. May 19, 2015.
262. Invited Presentation: "Multidrug Resistant TB in Children." XVIth Congress of the Latin American Society of Pediatric Infectious Diseases (SLIPE) and LXIIth Annual Congress of the Puerto Rican Society of Pediatrics. San Juan, Puerto Rico. June 25, 2015.
263. Invited Presentation: "Screening for Latent Tuberculosis Infection in Children." XVIth Congress of the Latin American Society of Pediatric Infectious Diseases (SLIPE) and LXIIth Annual Congress of the Puerto Rican Society of Pediatrics. San Juan, Puerto Rico. June 25, 2015.
264. Co-Convener Special Symposium: "Independent Assessment of National TB Prevalence Surveys, 2009-2014." 46<sup>th</sup> World Conference on Lung Health, Cape Town, South Africa. December 1, 2015.
265. Invited Presentation: "Independent Assessment of National TB Prevalence Surveys, 2009-2014." World Health Organization Global Task Force on TB Impact Measurement. Glion-sur-Montreux, Switzerland. April 9-12, 2016.
266. Course Director: "International Course in Applied Epidemiology" co-sponsored by the Rollins School of Public Health, Emory University and the Centers for Disease Control and Prevention. Atlanta, Georgia. September 26–October 21, 2016.
267. Invited Moderator: Symposium 48. "Shortened regimens for the treatment of multidrug resistant tuberculosis." 47<sup>th</sup> Union World Conference on Lung Health. Liverpool, UK. October 28, 2016.
268. Hubert Department of Global Health Faculty Seminar: "Global tuberculosis update: challenges and opportunities in achieving the UN Sustainable Development Goals." Emory University Rollins School of Public Health. Atlanta, Georgia. November 9, 2016.
269. Invited presentation: "Estimating tuberculosis cases and their economic costs averted in the United States over the past two decades." XX International Congress on Tuberculosis UITB-2016. Barcelona, Spain. November 22, 2016.
270. Invited CDC Preventive Medicine Grand Rounds: "Origin and Role of the Stop TB Partnership and its Ongoing Relevance in the Era of U.N. Sustainable

Development Goals and End TB Strategy.” Centers for Disease Control and Prevention. Atlanta, Georgia. December 7, 2016.

271. Invited presentation: “EIS Experiences and Global Update on Tuberculosis.” Hispanic Conference on Public Health (Conferencia Hispana de Salud Pública – CHISPA 2018). Dorado, Puerto Rico. August 11, 2018.
272. Invited Moderator: “Creating Consensus: Who, What, and How?” Tuberculosis Expert Panel Consultants. Regional Workshop on Latent Tuberculosis Infection. Latin American Thoracic Association (Asociación Latinoamericana de Tórax – ALAT). Monterrey, Mexico. August 23, 2018.
273. Invited presentation: “Diagnosis and Treatment of Latent TB Infection in Children.” International Course on Latent TB, Latin American Thoracic Association (Asociación Latinoamericana de Tórax – ALAT). Monterrey, Mexico. August 24, 2018.
274. Invited presentation: “Obstacles in the Implementation of a Latent TB Infection Program.” International Course on Latent TB, Latin American Thoracic Association (Asociación Latinoamericana de Tórax – ALAT). Monterrey, Mexico. August 24, 2018.
275. Focal point presentation: “Early Lessons from Prospective Country Evaluations”, 2nd Dissemination Workshop in Guatemala, Global Fund Technical Evaluation Reference Group’s Prospective Country Evaluation (PCE). Guatemala City, Guatemala. March 7, 2019.
276. Invited presentation: “Contact Investigations: Rationale & Framework for Action.” Satellite Session on TB Preventive Therapy. 50th UNION World Conference on Lung Health, Hyderabad, India. October 31, 2019.
277. Keynote Speaker: “How can we End global TB?”, 2020 World TB Day, Boston University School of Public Health (Virtual Session, March 24, 2020)
278. Co-Chair (with Dr. Yukari Manabe): Tuberculosis Workshop, ID Week 2020 (Virtual Session, October 13, 2020)
279. Chair: The Union late-breaker session on COVID-19. 51st Union World Conference on Lung Health. (Virtual Session, October 22, 2020)
280. Invited Panelist: Symposium #4. Clinical Group Symposium I: Marcolongo Lecture and Panel Discussion on TB control in the setting of COVID-19. American Society of Tropical Medicine and Hygiene, 69th Annual Meeting (Virtual Presentation, November 16, 2020)
281. Invited presentation: “Update: Tuberculosis contact investigations and use of shortened preventive therapy regimens.” XXIV International Congress on Tuberculosis UITB-2020. Barcelona, Spain. (Virtual presentation. November 16,

2020).

282. Invited Guest Editor (with Drs. Helen Cox and N. Sarita Shah). Int J TB Lung Dis Special thematic supplement on USAID-Johnson & Johnson bedaquiline donation program for expanded access to people with MDR TB; experiences in 9 countries (October 2020)
283. Invited International Speaker, Symposium 1: “Observations and Recommendations by the 2019 WHO–Gol Joint Monitoring Mission (JMM) on Tuberculosis.” 75<sup>th</sup> National Conference of Tuberculosis and Chest Diseases (NATCON 2020). <https://www.natcon2020.com/> (Virtual Conference, Hall A, December 19, 2020)
284. Co-Chair Virtual Steering Committee, TB Data Optimization Project, CDC/BMGF. Feb 1, 2021 (Dr. Jennifer Harris, Epidemiologist, DGHT/CGH/CDC)
285. 43<sup>rd</sup> TERG Meeting, Global Fund Against HIV/AIDS, TB, and Malaria. Virtual sessions: February 2-4, 2021
286. Invited Moderator, Virtual “TB Contact Investigation Summit,” TB Division, Office of Infectious Diseases, USAID. February 10-11 & 17, 2021
287. Invited Panelist, Virtual Kerala Health Conference – Making SDGs a reality. “Moving towards TB elimination- A call for action,” March 4, 2021
288. 94<sup>th</sup> American Epidemiological Society (AES) Virtual Conference. March 18-19, 2021
289. Invited Panelist and Moderator, Virtual World TB Day Congressional Briefing on COVID-19 Impacts on Global TB. (Organized by IDSA on behalf of TB Roundtable). March 24, 2021
290. 44<sup>th</sup> TERG Meeting, Global Fund Against HIV/AIDS, TB, and Malaria. Virtual sessions: June 3-4, 8-9, 2021
291. 45<sup>th</sup> TERG Meeting, Global Fund Against HIV/AIDS, TB, and Malaria. Virtual sessions: Sept 2, 3, 14, 2021
292. Co-Chair (with Dr. Gail H. Cassell), Committee of Innovations for Tackling Tuberculosis in the Time of COVID-19: A Two-Part Workshop, Forum on Microbial Threats, Board on Global Health, Health and Medicine Division, National Academies of Science, Engineering, and Medicine. (Virtual Workshops: July 22, September 14-16, 2021). <https://nap.nationalacademies.org/read/26404/chapter/1> and <https://nap.nationalacademies.org/read/26530/chapter/2#2>
293. Co-convener and Co-Moderator (with Dr. Yukari Manabe). TB Workshop, ID Week 2021 Virtual Conference. September 28, 2021
294. Invited presentation: COVID-19 Vaccines (Spanish virtual outreach session targeting Atlanta’s Hispanic Community). Informative Community Forum organized by Refugee Women’s Network. October 26, 2021

295. Invited plenary keynote presentation: “Parallels, Differences, and Mutual Lessons between TB and COVID-19 (Spanish: “Paralelismos, Diferencias, y Lecciones Mutuas entre TB y COVID-19”). XXV International Congress on Tuberculosis UITB-2021. (In-person presentation) Barcelona, Spain. November 16, 2021
296. Invited Facilitator. GH 501 Ethics Roundtable. Navigating Global Health Ethics (CNR Auditorium): Rollins School of Public Health, Emory University. Atlanta, Georgia. December 3, 2021
297. 46th TERG Meeting, Global Fund Against HIV/AIDS, TB, and Malaria (Virtual sessions). Feb 8-9, 2022
298. Guest Lecturer: EPI 542/ GH 562 Epidemiology of Tuberculosis. “Global Efforts to Control TB.” (Hybrid Session). Rollins School of Public Health, Emory university. March 3, 2022
299. Invited presentation: Summary of Proceedings of the National Academies of Science, Engineering, and Medicine Forum on Antimicrobial Threats: “Innovations for Tackling Tuberculosis in the Time of COVID-19: A Two-part Workshop Series (July 22 and Sept14-16, 2021).” 33rd Meeting of the International Task Force for Disease Eradication (ITFDE), The Carter Center. Atlanta, Georgia. March 14, 2022
300. Invited Moderator and Keynote Address: “Reimagining TB Elimination: Lessons from the COVID-19 Response.” New York City World TB Day, Global Tuberculosis Institute, Rutgers University and Bureau of Tuberculosis Control, New York City Department of Health and Mental Hygiene. Virtual Online Session. March 18, 2022
301. Introduction to Emory TB Center and NIH TB Research Advancement Center (TRAC) Award. (Co-presenter with Drs. Neel Gandhi and Jyothi Rengarajan). World TB Day Symposium. Emory School of Medicine Infectious Diseases Seminar. Atlanta, Georgia. March 24, 2022
302. Invited Speaker: “Global Impact of COVID-19 on TB Programs.” Research Conference, Emory-Ethiopia TB Research Training Program. Virtual Session. April 6, 2022
303. Invited Speaker: Global Impact of COVID-19 on Tuberculosis. Session 106. How COVID-19 is changing tuberculosis demographics, diagnostics, and treatment: Considerations for the Work Force. American Occupational Health Conference (AOHC) 2022. Salt Lake City, Utah. May 1, 2022
304. 47th Global Fund TERG Meeting, Global Fund Against HIV/AIDS, TB, and Malaria. Virtual sessions: May 4-5, 2022. In-person sessions: Global Health campus, Geneva, Switzerland. June 8-9, 2022
305. Invited Speaker: “Global Impact of COVID-19 on TB Programs.” Annual Research Conference, Emory-Georgia TB Research Training Program. Kazbegi, Republic of Georgia. July 6, 2022

306. Invited Presentation: “Global Tuberculosis Update and Impact of COVID-19.” Return Peace Corps Volunteer Reunion, Decatur, Georgia. July 16, 2022
307. Invited Moderator: “Airborne Infection Defense Platform” 2-day Webinar, Think20, Task Force 6 (Global Health Security and COVID-19), G20. Co-sponsored by Center for Health Administration and Policy Studies (CHAMPS), Universitas Indonesia, Stop TB Partnership, U.S. Agency for International Development (USAID). Virtual Webinar. August 2-3, 2022
308. Co-moderator (with Dr. Yukari Manabe), TB Workshop, ID Week 2022. Invited presenter: “Global TB/COVID-19 Update.” Washington, DC. October 19, 2022
309. Invited Presentation: “Rifapentine’s long and winding road to European patients.” XXVI International Congress on Tuberculosis UITB-2022. Barcelona, Spain. November 15, 2022. Barcelona, Spain
310. Invited Presentation: “Global Tuberculosis Situation, Impact of COVID-19, and Future Perspectives.” (Virtual presentation). 75th Anniversary of the Institute of Tropical Medicine, Central University of Venezuela. Caracas, Venezuela. November 30, 2022
311. Invited Presentation: “Elimination of Drug-resistant TB in Ethiopia: Lessons from U.S. & Global Experience.” 17th Tuberculosis Research Advisory Council (TRAC) Annual TB Research Conference & World TB Day Commemoration, Gondar, Ethiopia. March 22, 2023
312. Invited Presentation: “The Road to 2nd United Nations High-level Meeting on the Fight Against Tuberculosis.” Annual Research Conference. Emory-Georgia TB Research Training Program, Tsinandali, Georgia. October 18, 2023
313. Invited Presentation: “TB Preventive Therapy (TPT) in Persons with HIV.” Pan American Health Organization (PAHO) – Workshop to strengthen collaborative TB/HIV activities towards the elimination of AIDS mortality in Ecuador. (Virtual presentation). Quito, Ecuador. December 7, 2023
314. Invited joint presentation (with Drs. NS Shah and SS Kumar): “The 2<sup>nd</sup> United Nations High-level Meeting on the Fight Against Tuberculosis: What Does it Mean for Ending TB?” Emory/Georgia TB Research Advancement Center (TRAC). TB Works in Progress Seminar. Rollins School of Public Health, Emory University. Atlanta, Georgia. December 15, 2023.
315. Invited keynote address: “Tuberculosis – what’s past is prologue.” 2024 UCSF World TB Day Symposium & Curry International TB Center 30<sup>th</sup> Anniversary. San Francisco, California. March 22, 2024
316. Hubert Department of Global Health Noontime Seminar Series: “The 2nd United Nations High-level Meeting on the Fight Against Tuberculosis: What Does it Mean for Ending TB?” (Samhita Kumar, MPH, Kenneth G Castro, MD, Sarita Shah, MD, MPH). Rollins School of Public Health, Emory University, Atlanta, Georgia. March 27, 2024